<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Aliment Pharmacol Ther</journal-id><journal-id journal-id-type="iso-abbrev">Aliment. Pharmacol. Ther</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1365-2036</journal-id><journal-id journal-id-type="publisher-id">APT</journal-id><journal-title-group><journal-title>Alimentary Pharmacology &#x00026; Therapeutics</journal-title></journal-title-group><issn pub-type="ppub">0269-2813</issn><issn pub-type="epub">1365-2036</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7267115</article-id><article-id pub-id-type="doi">10.1111/apt.15779</article-id><article-id pub-id-type="publisher-id">APT15779</article-id><article-categories><subj-group subj-group-type="overline"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Review Articles</subject></subj-group></article-categories><title-group><article-title>Review article: prevention, diagnosis and management of COVID&#x02010;19 in the IBD patient</article-title><alt-title alt-title-type="left-running-head">AL&#x02010;ANI et al.</alt-title></title-group><contrib-group><contrib id="apt15779-cr-0001" contrib-type="author"><name><surname>Al&#x02010;Ani</surname><given-names>Aysha H.</given-names></name><xref ref-type="aff" rid="apt15779-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="apt15779-cr-0002" contrib-type="author"><name><surname>Prentice</surname><given-names>Ralley E.</given-names></name><xref ref-type="aff" rid="apt15779-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="apt15779-cr-0003" contrib-type="author"><name><surname>Rentsch</surname><given-names>Clarissa A.</given-names></name><xref ref-type="aff" rid="apt15779-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="apt15779-cr-0004" contrib-type="author"><name><surname>Johnson</surname><given-names>Doug</given-names></name><xref ref-type="aff" rid="apt15779-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="apt15779-cr-0005" contrib-type="author"><name><surname>Ardalan</surname><given-names>Zaid</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6952-0985</contrib-id><xref ref-type="aff" rid="apt15779-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="apt15779-cr-0006" contrib-type="author"><name><surname>Heerasing</surname><given-names>Neel</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0579-2062</contrib-id><xref ref-type="aff" rid="apt15779-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="apt15779-cr-0007" contrib-type="author"><name><surname>Garg</surname><given-names>Mayur</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9149-3589</contrib-id><xref ref-type="aff" rid="apt15779-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="apt15779-cr-0008" contrib-type="author"><name><surname>Campbell</surname><given-names>Sian</given-names></name><xref ref-type="aff" rid="apt15779-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="apt15779-cr-0009" contrib-type="author"><name><surname>Sasadeusz</surname><given-names>Joe</given-names></name><xref ref-type="aff" rid="apt15779-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="apt15779-cr-0010" contrib-type="author"><name><surname>Macrae</surname><given-names>Finlay A.</given-names></name><xref ref-type="aff" rid="apt15779-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="apt15779-cr-0011" contrib-type="author"><name><surname>Ng</surname><given-names>Siew C.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6850-4454</contrib-id><xref ref-type="aff" rid="apt15779-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="apt15779-cr-0012" contrib-type="author"><name><surname>Rubin</surname><given-names>David T.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5647-1723</contrib-id><xref ref-type="aff" rid="apt15779-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="apt15779-cr-0013" contrib-type="author" corresp="yes"><name><surname>Christensen</surname><given-names>Britt</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8746-4275</contrib-id><xref ref-type="aff" rid="apt15779-aff-0001">
<sup>1</sup>
</xref><address><email>britt.christensen@mh.org.au</email></address></contrib></contrib-group><aff id="apt15779-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Gastroenterology</named-content>
<institution>The Royal Melbourne Hospital</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Vic.</named-content>
<country country="AU">Australia</country>
</aff><aff id="apt15779-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Victorian Infectious Diseases Unit</named-content>
<institution>The Royal Melbourne Hospital</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Vic.</named-content>
<country country="AU">Australia</country>
</aff><aff id="apt15779-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Department of Medicine and Therapeutics</named-content>
<named-content content-type="organisation-division">Institute of Digestive Disease</named-content>
<named-content content-type="organisation-division">State Key Laboratory of Digestive Diseases</named-content>
<institution>Li Ka Shing Institute of Health Science</institution>
<institution>The Chinese University of Hong Kong</institution>
<city>Hong Kong Special Administrative Region</city>
<country country="CN">China</country>
</aff><aff id="apt15779-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Inflammatory Bowel Disease Center</named-content>
<institution>University of Chicago Medicine</institution>
<city>Chicago</city>
<named-content content-type="country-part">IL</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Britt Christensen, The Royal Melbourne Hospital, Gastroenterology Department, 300 Grattan St, Parkville, Vic., Australia.<break/>
Email: <email>britt.christensen@mh.org.au</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>5</month><year>2020</year></pub-date><elocation-id>10.1111/apt.15779</elocation-id><history><date date-type="received"><day>13</day><month>4</month><year>2020</year></date><date date-type="rev-recd"><day>15</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>17</day><month>4</month><year>2020</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2020 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2020 John Wiley &#x00026; Sons Ltd</copyright-statement><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:APT-9999-na.pdf"/><abstract id="apt15779-abs-0001"><title>Summary</title><sec id="apt15779-sec-0001"><title>Background</title><p>The current COVID&#x02010;19 pandemic, caused by SARS&#x02010;CoV&#x02010;2, has emerged as a public health emergency. All nations are seriously challenged as the virus spreads rapidly across the globe with no regard for borders. The primary management of IBD involves treating uncontrolled inflammation with most patients requiring immune&#x02010;based therapies. However, these therapies may weaken the immune system and potentially place IBD patients at increased risk of infections and infectious complications including those from COVID&#x02010;19.</p></sec><sec id="apt15779-sec-0002"><title>Aim</title><p>To summarise the scale of the COVID&#x02010;19 pandemic, review unique concerns regarding IBD management and infection risk during the pandemic and assess COVID&#x02010;19 management options and drug interactions in the IBD population.</p></sec><sec id="apt15779-sec-0003"><title>Methods</title><p>A literature review on IBD, SARS&#x02010;CoV&#x02010;2 and COVID&#x02010;19 was undertaken and relevant literature was summarised and critically examined.</p></sec><sec id="apt15779-sec-0004"><title>Results</title><p>IBD patients do not appear to be more susceptible to SARS&#x02010;CoV&#x02010;2 infection and there is no evidence of an association between IBD therapies and increased risk of COVID&#x02010;19. IBD medication adherence should be encouraged to prevent disease flare but where possible high&#x02010;dose systemic corticosteroids should be avoided. Patients should exercise social distancing, optimise co&#x02010;morbidities and be up to date with influenza and pneumococcal vaccines. If a patient develops COVID&#x02010;19, immune suppressing medications should be withheld until infection resolution and if trial medications for COVID&#x02010;19 are being considered, potential drug interactions should be checked.</p></sec><sec id="apt15779-sec-0005"><title>Conclusion</title><p>IBD patient management presents a challenge in the current COVID&#x02010;19 pandemic. The primary focus should remain on keeping bowel inflammation controlled and encouraging medication adherence.</p></sec></abstract><counts><fig-count count="0"/><table-count count="4"/><page-count count="19"/><word-count count="32774"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>edited-state</meta-name><meta-value>corrected-proof</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.3 mode:remove_FC converted:03.06.2020</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="apt15779-cit-1001">
<string-name>
<surname>Al&#x02010;Ani</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Prentice</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Rentsch</surname>
<given-names>CA</given-names>
</string-name>, et al. <article-title>Review article: prevention, diagnosis and management of COVID&#x02010;19 in the IBD patient</article-title>. <source xml:lang="en">Aliment Pharmacol Ther</source>. <year>2020</year>;<volume>00</volume>:<fpage>1</fpage>&#x02013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1111/apt.15779</pub-id>
</mixed-citation>
</p><fn-group id="apt15779-ntgp-0001"><fn id="apt15779-note-0001"><p>The Handling Editor for this article was Professor Jonathan Rhodes, and this uncommissioned review was accepted for publication after full peer&#x02010;review.</p></fn><fn id="apt15779-note-0002"><p>Aysha&#x000a0;H. Al&#x02010;Ani and Ralley E. Prentice should be considered joint first authors.</p></fn></fn-group></notes></front><body id="apt15779-body-0001"><sec id="apt15779-sec-0006"><label>1</label><title>INTRODUCTION</title><p>In December 2019, reports of a novel coronavirus, since named SARS&#x02010;CoV&#x02010;2, emerged from Wuhan, central Hubei Province, China.<xref rid="apt15779-bib-0001" ref-type="ref">
<sup>1</sup>
</xref>, <xref rid="apt15779-bib-0002" ref-type="ref">
<sup>2</sup>
</xref>, <xref rid="apt15779-bib-0003" ref-type="ref">
<sup>3</sup>
</xref> The virus causes the disease COVID&#x02010;19, which manifests as a severe acute respiratory illness that can be complicated by acute respiratory distress syndrome (ARDS), multiorgan failure and even death.<xref rid="apt15779-bib-0003" ref-type="ref">
<sup>3</sup>
</xref> Following rapid spread of the virus across the globe, the World Health Organisation (WHO) declared COVID&#x02010;19 a pandemic on 11 March 2020.<xref rid="apt15779-bib-0002" ref-type="ref">
<sup>2</sup>
</xref> There are currently almost 2&#x000a0;million confirmed cases across more than 200 countries with a total death count greater than 100&#x000a0;000 at the time of writing.<xref rid="apt15779-bib-0002" ref-type="ref">
<sup>2</sup>
</xref> As the pandemic expands, there has been increasing concern regarding the impact of COVID&#x02010;19 on patients with IBD.</p><p>The primary management of IBD involves treating uncontrolled inflammation with a significant number of patients requiring immune&#x02010;based therapies.<xref rid="apt15779-bib-0004" ref-type="ref">
<sup>4</sup>
</xref> In the last decade, there has been a considerable expansion of the therapeutic armamentarium for patients with IBD to include immunomodulators, TNF&#x000a0;antagonists, non&#x02010;TNF&#x02010;targeted biologics and targeted small molecule therapies.<xref rid="apt15779-bib-0005" ref-type="ref">
<sup>5</sup>
</xref> However, these therapies, in addition to malnutrition which can complicate IBD, may weaken the immune system and potentially place IBD patients at increased risk of infections and infectious complications.<xref rid="apt15779-bib-0006" ref-type="ref">
<sup>6</sup>
</xref>
</p><p>Consequently, there is a concern that IBD patients are at greater risk of developing COVID&#x02010;19 and at increased risk of progressing to a more severe clinical course or even death compared to the general population. In addition, if an IBD patient develops COVID&#x02010;19, there is a lack of guidance on medication management and concern regarding drug interactions if trial medications are utilised to treat COVID&#x02010;19.</p><p>Therefore the aim of this review is to summarise the evidence and discuss in detail the data regarding the risks of developing COVID&#x02010;19, strategies that can be implemented to reduce these risks and issues surrounding the treatment of COVID&#x02010;19, including potential drug interactions and IBD medication management, in the IBD patient cohort.</p></sec><sec id="apt15779-sec-0007"><label>2</label><title>CORONAVIRUSES</title><p>Coronaviruses (of the family coronaviridae) are a group of related single&#x02010;stranded, positive sense, enveloped RNA viruses. They are the largest known RNA viruses, ranging from 26 to32 kilobases in size.<xref rid="apt15779-bib-0007" ref-type="ref">
<sup>7</sup>
</xref> They are named after their appearance under electron microscopy, showing crown or halo (solar corona)&#x02010;like spikes (virions) on their surface. <xref rid="apt15779-bib-0008" ref-type="ref">
<sup>8</sup>
</xref> These viruses are capable of causing illness in humans and other mammals as well as birds.</p><p>Human coronaviruses (HCoVs)&#x000a0;were first discovered in 1960. There are currently seven known human coronaviruses: Human coronavirus 229E&#x000a0;(HCoV&#x02010;229E), Human coronavirus OC43&#x000a0;(HCoV&#x02010;OC43), Human coronavirus HKU1&#x000a0;(HCoV&#x02010;HKU1), Human coronavirus NL63&#x000a0;(HCoV&#x02010;NL63), Severe Acute Respiratory Syndrome Coronavirus (SARS&#x02010;CoV), Middle Eastern Respiratory Syndrome Coronavirus (MERS&#x02010;CoV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS&#x02010;CoV&#x02010;2). <xref rid="apt15779-bib-0009" ref-type="ref">
<sup>9</sup>
</xref> These viruses are all known to cause respiratory symptoms ranging broadly in severity, both between the different viruses and in different hosts infected with the same virus. Most spread easily and result in relatively mild illness in immunocompetent patients, with certain strains being responsible for almost 30% of the common cold.<xref rid="apt15779-bib-0010" ref-type="ref">
<sup>10</sup>
</xref>
</p><p>Other coronaviruses (CoVs), including the SARS&#x02010;CoV and the MERS&#x02010;CoV, have previously emerged as epidemics with significant mortality and socioeconomic impact. Compared to SARS&#x02010;CoV&#x02010;2, MERS&#x02010;CoV causes a much more severe illness, with a case&#x02010;fatality rate&#x000a0;(CFR) of up to 30%, but appears to have a lower person&#x02010;to&#x02010;person transmission, limiting its global impact.<xref rid="apt15779-bib-0005" ref-type="ref">
<sup>5</sup>
</xref> There are still new cases of MERS being reported today.<xref rid="apt15779-bib-0011" ref-type="ref">
<sup>11</sup>
</xref> Similarly, the SARS&#x02010;CoV outbreak in 2002&#x02010;2003 had a high CFR (9.6%), but its reduced infectivity compared with SARS&#x02010;CoV&#x02010;2 lessened its overall impact.<xref rid="apt15779-bib-0012" ref-type="ref">
<sup>12</sup>
</xref> This outbreak appears to have been contained.<xref rid="apt15779-bib-0012" ref-type="ref">
<sup>12</sup>
</xref> SARS&#x02010;CoV&#x02010;2 is the first pandemic coronavirus. Therefore, it poses a threat of uncertain dimensions and represents uncharted territory for the public and global healthcare systems alike.<xref rid="apt15779-bib-0002" ref-type="ref">
<sup>2</sup>
</xref>, <xref rid="apt15779-bib-0003" ref-type="ref">
<sup>3</sup>
</xref>
</p></sec><sec id="apt15779-sec-0008"><label>3</label><title>SARS&#x02010;COV&#x02010;2 VIRUS AND COVID&#x02010;19</title><p>SARS&#x02010;CoV&#x02010;2, the virus previously known as novel 2019&#x02010;coronavirus, causes the disease COVID&#x02010;19. It was first discovered following the reports of an outbreak of pneumonia in China, with initial infections linked to a single seafood market.<xref rid="apt15779-bib-0001" ref-type="ref">
<sup>1</sup>
</xref>, <xref rid="apt15779-bib-0013" ref-type="ref">
<sup>13</sup>
</xref> Genetic studies have shown its genetic sequence is 82% similar to SARS&#x02010;CoV, and 89% similar to bat&#x02010;SL&#x02010;CoVZC45 and bat&#x02010;SL&#x02010;CoVZXC21, leading to the postulation that bats served as reservoir host for the new coronavirus&#x02019; progenitor.<xref rid="apt15779-bib-0014" ref-type="ref">
<sup>14</sup>
</xref> Human transmission is thought to have been facilitated by an animal intermediate host, currently hypothesised to be a pangolin.<xref rid="apt15779-bib-0015" ref-type="ref">
<sup>15</sup>
</xref>
</p><sec id="apt15779-sec-0009"><label>3.1</label><title>Transmission</title><p>Human&#x02010;to&#x02010;human transmission is believed to be predominantly via direct contact, exhaled droplets and fomites from an infected individual.<xref rid="apt15779-bib-0016" ref-type="ref">
<sup>16</sup>
</xref> SARS&#x02010;CoV&#x02010;2 can also be detected in saliva, urine and the gastrointestinal tract in both biopsy specimens and stools, although their role in transmission remains unclear.<xref rid="apt15779-bib-0017" ref-type="ref">
<sup>17</sup>
</xref>, <xref rid="apt15779-bib-0018" ref-type="ref">
<sup>18</sup>
</xref>, <xref rid="apt15779-bib-0019" ref-type="ref">
<sup>19</sup>
</xref> Data suggest it is more easily transmitted than seasonal influenza based on a basic reproduction number (R<sub>0</sub> &#x02010; the&#x000a0;expected number of cases directly generated by one case in the population) of 2&#x02010;2.5.<xref rid="apt15779-bib-0020" ref-type="ref">
<sup>20</sup>
</xref>
</p><p>Entry of coronaviruses into human target cells requires spike (S) protein binding to a cellular receptor followed by S protein priming by host proteases to facilitate cell entry.<xref rid="apt15779-bib-0021" ref-type="ref">
<sup>21</sup>
</xref> SARS&#x02010;CoV&#x02010;2 human&#x02010;to&#x02010;human transmission is enabled by the interaction of the SARS&#x02010;CoV&#x02010;2 S&#x02010;protein with the human angiotensin&#x02010;converting enzyme 2 (ACE2) receptor.<xref rid="apt15779-bib-0017" ref-type="ref">
<sup>17</sup>
</xref>, <xref rid="apt15779-bib-0018" ref-type="ref">
<sup>18</sup>
</xref> Transmission occurs when the virus enters the nose, mouth or eyes, and potentially the digestive system and attaches to cells that produce ACE2. ACE2 are found in multiple organs and are highly expressed in lung AT2 cells, enterocytes of the small intestine and colon.<xref rid="apt15779-bib-0022" ref-type="ref">
<sup>22</sup>
</xref>, <xref rid="apt15779-bib-0023" ref-type="ref">
<sup>23</sup>
</xref> Once the virus is attached to ACE2 it uses the host serine protease TMPRSS2 for S priming allowing fusion of viral and cellular membranes and viral entry into the cell.<xref rid="apt15779-bib-0021" ref-type="ref">
<sup>21</sup>
</xref>
</p><p>Once a person develops initial symptoms of COVID&#x02010;19, respiratory viral shedding occurs for a median of 20&#x000a0;days in survivors and is sustained until death in nonsurvivors.<xref rid="apt15779-bib-0024" ref-type="ref">
<sup>24</sup>
</xref> Of note, prolonged shedding has been demonstrated with other coronaviruses in immunocompromised patients<xref rid="apt15779-bib-0025" ref-type="ref">
<sup>25</sup>
</xref> and in immunocompromised animals with MERS&#x02010;CoV.<xref rid="apt15779-bib-0025" ref-type="ref">
<sup>25</sup>
</xref>, <xref rid="apt15779-bib-0026" ref-type="ref">
<sup>26</sup>
</xref> However, the implications of this prolonged shedding are unknown as virus detected by PCR does not necessarily indicate viable virus or infectivity; a study of nine COVID&#x02010;19 patients demonstrated that infectious virus was only isolated from samples taken before day 8 of symptom onset despite ongoing high viral loads and shedding after this time point.<xref rid="apt15779-bib-0027" ref-type="ref">
<sup>27</sup>
</xref> Asymptomatic people are also potential sources of SARS&#x02010;CoV&#x02010;2 as transmission may occur in the pre&#x02010;clinical period (2&#x02010;14&#x000a0;days) or from an oligosymptomatic individual.<xref rid="apt15779-bib-0027" ref-type="ref">
<sup>27</sup>
</xref>, <xref rid="apt15779-bib-0028" ref-type="ref">
<sup>28</sup>
</xref> Furthermore the virus has been detected in up to 50% of stool specimens and can remain positive for viral RNA following negative respiratory samples in more than 20% of SARS&#x02010;CoV&#x02010;2 patients.<xref rid="apt15779-bib-0019" ref-type="ref">
<sup>19</sup>
</xref>, <xref rid="apt15779-bib-0022" ref-type="ref">
<sup>22</sup>
</xref>, <xref rid="apt15779-bib-0029" ref-type="ref">
<sup>29</sup>
</xref> These characteristics may have implications regarding isolation and decision&#x02010;making for IBD patients who are infected with SARS&#x02010;CoV&#x02010;2 although there are no evidence&#x02010;based guidelines on this currently.</p></sec><sec id="apt15779-sec-0010"><label>3.2</label><title>Symptoms</title><p>The major clinical manifestations of COVID&#x02010;19 are fever (44% on admission and 89% during admission), dry cough (68%), shortness of breath (19%), diarrhoea/vomiting/abdominal pain (20%), generalised myalgia/arthralgia (15%), headache (14%), malaise and bilateral interstitial pneumonia.<xref rid="apt15779-bib-0015" ref-type="ref">
<sup>15</sup>
</xref>, <xref rid="apt15779-bib-0019" ref-type="ref">
<sup>19</sup>
</xref>, <xref rid="apt15779-bib-0030" ref-type="ref">
<sup>30</sup>
</xref> COVID&#x02010;19 pneumonia manifests with chest CT imaging abnormalities, even in asymptomatic patients, with rapid evolution from focal unilateral to diffuse bilateral ground&#x02010;glass opacities that progress to or co&#x02010;exist with consolidations within 1&#x02010;3&#x000a0;weeks. <xref rid="apt15779-bib-0015" ref-type="ref">
<sup>15</sup>
</xref>
</p><p>While the mechanism of COVID&#x02010;19 induced gastrointestinal symptoms remains to be clarified, enteric symptoms may occur due to malabsorption secondary to direct damage of the invaded enterocyte in the setting of a viral infection.<xref rid="apt15779-bib-0018" ref-type="ref">
<sup>18</sup>
</xref> Furthermore, there is a recent case report of a possible SARS&#x02010;CoV&#x02010;2 gastrointestinal infection causing acute haemorrhagic colitis and signalling COVID&#x02010;19 disease.<xref rid="apt15779-bib-0031" ref-type="ref">
<sup>31</sup>
</xref> It is not clear if gastrointestinal symptom rates secondary to COVID&#x02010;19 differ in patients with IBD but if an IBD patients presents with worsening gastrointestinal symptoms, COVID&#x02010;19 infection should be considered as a differential.</p></sec><sec id="apt15779-sec-0011"><label>3.3</label><title>Demographics</title><p>The median age of an infected individual is 51&#x000a0;years old and the majority of infected individuals range from 30 to 69&#x000a0;years.<xref rid="apt15779-bib-0016" ref-type="ref">
<sup>16</sup>
</xref> Fifty&#x02010;one percent of reported cases is male. Healthcare workers may be at increased risk of infection secondary to close contact with infected patients and exposure to aerosolised virus from medical equipment and procedures including endoscopy.<xref rid="apt15779-bib-0032" ref-type="ref">
<sup>32</sup>
</xref> In China healthcare workers made up 3.5% of COVID&#x02010;19 patients and Italy have reported that 20% of its responding healthcare work force is being infected.<xref rid="apt15779-bib-0017" ref-type="ref">
<sup>17</sup>
</xref>, <xref rid="apt15779-bib-0033" ref-type="ref">
<sup>33</sup>
</xref> Current data suggest that children under the age of 18&#x000a0;years have a low infection rate (2.4%), with a large proportion being identified through contact tracing in adults rather than through symptomatology.<xref rid="apt15779-bib-0016" ref-type="ref">
<sup>16</sup>
</xref>
</p></sec><sec id="apt15779-sec-0012"><label>3.4</label><title>Disease course</title><p>The median incubation period for SARS&#x02010;CoV&#x02010;2 is 4&#x02010;5&#x000a0;days, with most patients having symptom onset before 14&#x000a0;days, but there have been cases with longer incubation.<xref rid="apt15779-bib-0034" ref-type="ref">
<sup>34</sup>
</xref> A mean interval of 9.1&#x02010;12.5&#x000a0;days between illness onset and hospitalisation has been documented highlighting the challenge in the identification and isolation of individuals at an early stage of disease.<xref rid="apt15779-bib-0035" ref-type="ref">
<sup>35</sup>
</xref> In recovered cases, the median time from initial symptoms to discharge from hospital was 22&#x000a0;days and in those that succumbed the average time to death was 18.5&#x000a0;days.<xref rid="apt15779-bib-0035" ref-type="ref">
<sup>35</sup>
</xref>
</p><p>Overall CFR of COVID&#x02010;19 are estimated to be approximately 1%&#x02010;2%, rising to more than 15% in patients aged 80&#x000a0;years and over.<xref rid="apt15779-bib-0036" ref-type="ref">
<sup>36</sup>
</xref> Current WHO data surmise that most cases of COVID&#x02010;19 have mild to moderate disease (80%) with 13.8% experiencing severe disease defined by the following signs and symptoms within 24&#x02010;48&#x000a0;hours: shortness of breath; tachypnoea &#x0003e;30 breaths per minute; hypoxia &#x0003c;93%; hypoxaemia with PaO<sub>2</sub>/FiO<sub>2</sub> ratio&#x000a0;&#x0003c;&#x000a0;300 and/or pulmonary infiltrates &#x0003e;50% of the lung field.<xref rid="apt15779-bib-0016" ref-type="ref">
<sup>16</sup>
</xref> Critical infections occur in 6.1% and are exemplified by septic shock, respiratory failure and/or multiorgan failure.<xref rid="apt15779-bib-0001" ref-type="ref">
<sup>1</sup>
</xref>, <xref rid="apt15779-bib-0016" ref-type="ref">
<sup>16</sup>
</xref> Approximately one quarter of hospitalised patients require intensive care and 4.3% die.<xref rid="apt15779-bib-0001" ref-type="ref">
<sup>1</sup>
</xref> The primary reason for transfer to ICU is the development of organ dysfunction with ARDS being the main catalyst.<xref rid="apt15779-bib-0001" ref-type="ref">
<sup>1</sup>
</xref>
</p></sec><sec id="apt15779-sec-0013"><label>3.5</label><title>Risk factors</title><p>Risk factors for contracting COVID&#x02010;19 have not been fully elucidated. Healthcare professionals are at greater risk secondary to increased exposure<xref rid="apt15779-bib-0032" ref-type="ref">
<sup>32</sup>
</xref> and it is thought that smoking may exacerbate contraction.<xref rid="apt15779-bib-0037" ref-type="ref">
<sup>37</sup>
</xref> For all patients with COVID&#x02010;19, severity and mortality is associated with age (median age 66&#x000a0;years for critically ill vs 51&#x000a0;years in the overall patient population) and underlying cardiovascular disease, hypertension, chronic pulmonary disease, diabetes and cancer.<xref rid="apt15779-bib-0016" ref-type="ref">
<sup>16</sup>
</xref>, <xref rid="apt15779-bib-0017" ref-type="ref">
<sup>17</sup>
</xref>, <xref rid="apt15779-bib-0038" ref-type="ref">
<sup>38</sup>
</xref> Severe COVID&#x02010;19 is less common in children with reports suggesting approximately 5% develop severe disease and 0.6% become critical.<xref rid="apt15779-bib-0039" ref-type="ref">
<sup>39</sup>
</xref> The crude fatality rate is higher in males (4.7%) vs females (2.8%) and smokers.<xref rid="apt15779-bib-0016" ref-type="ref">
<sup>16</sup>
</xref>, <xref rid="apt15779-bib-0017" ref-type="ref">
<sup>17</sup>
</xref>, <xref rid="apt15779-bib-0035" ref-type="ref">
<sup>35</sup>
</xref> Risk factors are summarised in Table&#x000a0;<xref rid="apt15779-tbl-0001" ref-type="table">1</xref>.</p><table-wrap id="apt15779-tbl-0001" xml:lang="en" content-type="Table" orientation="portrait" position="float"><label>Table 1</label><caption><p>hospital pharmacy for solution compounded from COVID&#x02010;19 and developing severe complications</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><tbody><tr><td align="left" rowspan="1" colspan="1">Possible risk factors for COVID&#x02010;19 infection<xref rid="apt15779-bib-0115" ref-type="ref">
<sup>115</sup>
</xref>, <xref rid="apt15779-bib-0116" ref-type="ref">
<sup>116</sup>
</xref>, <xref rid="apt15779-bib-0117" ref-type="ref">
<sup>117</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Smoker</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Healthcare worker</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Nursing&#x02010;home/community living environment</td></tr><tr><td align="left" rowspan="1" colspan="1">Possible risk factors for developing severe/critical COVID&#x02010;19<xref rid="apt15779-bib-0017" ref-type="ref">
<sup>17</sup>
</xref>, <xref rid="apt15779-bib-0019" ref-type="ref">
<sup>19</sup>
</xref>, <xref rid="apt15779-bib-0116" ref-type="ref">
<sup>116</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age&#x000a0;&#x0003e;&#x000a0;50</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diabetes</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypertension</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Malignancy</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">COPD</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Smoker</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lymphopenia</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Neutropenia</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Higher LDH and D&#x02010;dimer levels &#x0003e;1&#x000a0;&#x000b5;g/mL on admission</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Post&#x02010;operative setting</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Corticosteroids</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">?Diarrhoea</td></tr><tr><td align="left" rowspan="1" colspan="1">Further risk factors for death if admitted to ICU<xref rid="apt15779-bib-0017" ref-type="ref">
<sup>17</sup>
</xref>, <xref rid="apt15779-bib-0116" ref-type="ref">
<sup>116</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Tachycardia</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lymphopenia</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypoxia</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Coagulopathy</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions></table-wrap><p>Specific risk factors for developing COVID&#x02010;19 in IBD patients are yet to be determined. For lower respiratory tract infections with seasonal (non&#x02010;COVID&#x02010;19) coronavirus, risk factors in other immunocompromised patient groups have included age &#x0003e;50&#x000a0;years, receipt of corticosteroids, lymphopenia and neutropenia.<xref rid="apt15779-bib-0026" ref-type="ref">
<sup>26</sup>
</xref>, <xref rid="apt15779-bib-0040" ref-type="ref">
<sup>40</sup>
</xref> For IBD patients, the greatest risk factor for general immunosuppression and infections remains pharmacological.<xref rid="apt15779-bib-0041" ref-type="ref">
<sup>41</sup>
</xref>, <xref rid="apt15779-bib-0042" ref-type="ref">
<sup>42</sup>
</xref> Nutritional status, co&#x02010;morbidities, age and disease activity also contribute.<xref rid="apt15779-bib-0042" ref-type="ref">
<sup>42</sup>
</xref>, <xref rid="apt15779-bib-0043" ref-type="ref">
<sup>43</sup>
</xref> Of these, malnutrition (OR: 6.26 [95% CI: 1.20&#x02010;32.78])<xref rid="apt15779-bib-0041" ref-type="ref">
<sup>41</sup>
</xref>, <xref rid="apt15779-bib-0042" ref-type="ref">
<sup>42</sup>
</xref> and disease activity (OR: 3.35 [95%CI: 1.23&#x02010;9.23, <italic>P</italic>&#x000a0;=&#x000a0;0.02])<xref rid="apt15779-bib-0044" ref-type="ref">
<sup>44</sup>
</xref> are significant nonpharmacological risk factors that are modifiable for infection and therefore nutritional support and medical treatment aiming for disease control should be optimised.<xref rid="apt15779-bib-0041" ref-type="ref">
<sup>41</sup>
</xref>, <xref rid="apt15779-bib-0042" ref-type="ref">
<sup>42</sup>
</xref> Furthermore, low vitamin D levels are prevalent in IBD patients and may be associated with an increased risk and/or severity of influenza and COVID&#x02010;19.<xref rid="apt15779-bib-0045" ref-type="ref">
<sup>45</sup>
</xref>, <xref rid="apt15779-bib-0046" ref-type="ref">
<sup>46</sup>
</xref> Vitamin D increases anti&#x02010;inflammatory cytokines and lowers viral replication, which in turn may reduce pro&#x02010;inflammatory cytokines that propagate lung injury and ARDS.<xref rid="apt15779-bib-0045" ref-type="ref">
<sup>45</sup>
</xref>, <xref rid="apt15779-bib-0046" ref-type="ref">
<sup>46</sup>
</xref>, <xref rid="apt15779-bib-0047" ref-type="ref">
<sup>47</sup>
</xref> Therefore assessment of vitamin D and supplementation when it is low is reasonable.</p><p>As gastrointestinal tract permeability may be increased in IBD patients<xref rid="apt15779-bib-0018" ref-type="ref">
<sup>18</sup>
</xref> with higher expression of ACE2 in inflamed bowel,<xref rid="apt15779-bib-0048" ref-type="ref">
<sup>48</sup>
</xref> there is also a theoretical increased risk of SARS&#x02010;CoV&#x02010;2 infection via the gut in IBD patients. Despite this, there is no current evidence of increased infection rates or worse disease severity of COVID&#x02010;19 in IBD patients. Indeed, so far, no patient with IBD has been reported to have contracted COVID&#x02010;19 from the tertiary IBD centres in Wuhan where the virus originated<xref rid="apt15779-bib-0049" ref-type="ref">
<sup>49</sup>
</xref> and, despite IBD being a reasonably common condition, very low rates have been described in an international COVID&#x02010;IBD registry as of 11 April 2020. At time of writing, 457 (270 Crohn's disease [CD]; 185 UC/unspecified) cases of COVID&#x02010;19 in IBD had been reported with 26% of CD and 36% of ulcerative colitis (UC) patients requiring hospitalisation and 3% of CD and 5% of UC patients requiring ICU. Fifteen deaths have been reported.<xref rid="apt15779-bib-0050" ref-type="ref">
<sup>50</sup>
</xref> This appears to be a notable under&#x02010;representation of COVID&#x02010;19 infection in IBD patients compared to the prevalence of IBD and COVID&#x02010;19 separately in the community. As yet, it is unclear if this is secondary to low COVID&#x02010;19 infection rates or to significant under&#x02010;reporting of COVID&#x02010;19 infection in IBD patients.</p></sec><sec id="apt15779-sec-0014"><label>3.6</label><title>Diagnosis</title><p>A diagnosis of COVID&#x02010;19 should be considered in patients who display fever, cough, anosmia, nausea, vomiting and diarrhoea. Of note, a subgroup of patients may present with mild disease marked by the presence of diarrhoea initially and these patients often experience delayed diagnosis compared to those that present with respiratory symptoms.<xref rid="apt15779-bib-0051" ref-type="ref">
<sup>51</sup>
</xref> Biochemical markers of COVID&#x02010;19 include lymphopenia, thrombocytopenia and leukopenia as well as elevated C&#x02010;reactive protein (CRP), which may also correlate with severe disease. <xref rid="apt15779-bib-0017" ref-type="ref">
<sup>17</sup>
</xref> Less commonly, there may also be elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatine kinase (CK) and D&#x02010;dimer.<xref rid="apt15779-bib-0017" ref-type="ref">
<sup>17</sup>
</xref>
</p><p>Recommendations on whom to test for COVID&#x02010;19 will vary depending on the local guidelines, availability of testing kits and regional transmission dynamics. In high&#x02010;risk settings where an outbreak has occurred, all patients with clinical features consistent with COVID&#x02010;19 should be considered for testing. In non&#x02010;outbreak areas, a case of COVID&#x02010;19 should be suspected and tested for if a patient has clinical features suggestive of COVID&#x02010;19 and fits epidemiologic criteria for example international travel or contact with a confirmed COVID&#x02010;19 case. A patient is also considered a suspect case of COVID&#x02010;19 regardless of their history if they are admitted to hospital with acute respiratory illness or unexplained fever.</p><p>Diagnosis of COVID&#x02010;19 is via nucleic acid testing of nasopharyngeal and oropharyngeal swabs.<xref rid="apt15779-bib-0052" ref-type="ref">
<sup>52</sup>
</xref> Serology testing is currently not widely available. It is important to ensure that routine local protocols for testing in acute pneumonia/pneumonitis are also followed, such as bacterial cultures, urinary antigen testing, acute and convalescent serology and respiratory virus panels. At this stage, faecal sampling is not standard; however, this may be indicated in those with gastrointestinal symptoms. A positive test for COVID&#x02010;19 must be immediately notified to the relevant communicable diseases agency.<xref rid="apt15779-bib-0052" ref-type="ref">
<sup>52</sup>
</xref>
</p></sec></sec><sec id="apt15779-sec-0015"><label>4</label><title>MANAGEMENT OF IMMUNOSUPPRESSION WITH COVID&#x02010;19</title><p>Despite a lack of evidence demonstrating any increased susceptibility to COVID&#x02010;19,<xref rid="apt15779-bib-0050" ref-type="ref">
<sup>50</sup>
</xref> medications used in the management of IBD have been shown to increase the risk of respiratory tract infections and serious infections to varying degrees (Table&#x000a0;<xref rid="apt15779-tbl-0002" ref-type="table">2</xref>). However, theoretically, there may also be some beneficial effects seen with certain immunosuppressive medications, given the cause of death in COVID&#x02010;19 is&#x000a0;a cytokine storm resulting in ARDS.</p><table-wrap id="apt15779-tbl-0002" xml:lang="en" content-type="Table" orientation="portrait" position="float"><label>Table 2</label><caption><p>IBD medications and infection risk</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">&#x000a0;</th><th align="left" valign="top" rowspan="1" colspan="1">Risk of respiratory tract infections</th><th align="left" valign="top" rowspan="1" colspan="1">Risk of serious infections</th></tr></thead><tbody><tr><td align="left" colspan="3" rowspan="1">Steroids</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prednisolone</td><td align="left" rowspan="1" colspan="1">
<p>URTI for influenza compared to placebo
<list list-type="bullet" id="apt15779-list-0008"><list-item><p>OR 1.22 (95% CI, 1.08&#x02010;1.38)<xref rid="apt15779-bib-0062" ref-type="ref">
<sup>62</sup>
</xref>
</p></list-item></list>
</p>
<p>LRTI compared to placebo
<list list-type="bullet" id="apt15779-list-0009"><list-item><p>OR 3.62 (95% CI 3.30&#x02010;3.98)<xref rid="apt15779-bib-0062" ref-type="ref">
<sup>62</sup>
</xref>
</p></list-item></list>
</p>
</td><td align="left" rowspan="1" colspan="1">OR 1.92 (95% CI 0.36&#x02010;10.21) compared to placebo<xref rid="apt15779-bib-0063" ref-type="ref">
<sup>63</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Budesonide</td><td align="left" rowspan="1" colspan="1">No increase in adverse events compared with placebo<xref rid="apt15779-bib-0118" ref-type="ref">
<sup>118</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">
<p>RR 0.97 (95% CI 0.76&#x02010;1.13) compared to placebo<xref rid="apt15779-bib-0118" ref-type="ref">
<sup>118</sup>
</xref>
</p>
<p>OR 0.73 (95% CI 0.36&#x02010;1.50) Budesonide MMX compared to placebo<xref rid="apt15779-bib-0069" ref-type="ref">
<sup>69</sup>
</xref>
</p>
<p>OR 0.94 (95% CI 0.56&#x02010;1.59) Budesonide compared to placebo<xref rid="apt15779-bib-0069" ref-type="ref">
<sup>69</sup>
</xref>
</p>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Beclomethasone</td><td align="left" rowspan="1" colspan="1">No increase in adverse events compared with placebo<xref rid="apt15779-bib-0119" ref-type="ref">
<sup>119</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">
<p>OR 0.30 (95% CI 0.01&#x02010;8.29) compared to placebo<xref rid="apt15779-bib-0069" ref-type="ref">
<sup>69</sup>
</xref>
</p>
<p>OR 3.32 (95% CI 0.13&#x02010;84.9) compared to prednisolone <xref rid="apt15779-bib-0069" ref-type="ref">
<sup>69</sup>
</xref>
</p>
</td></tr><tr><td align="left" colspan="3" rowspan="1">Immunomodulators</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Thiopurines</td><td align="left" rowspan="1" colspan="1">2.1 per patient&#x02010;years<xref rid="apt15779-bib-0070" ref-type="ref">
<sup>70</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">OR 0.143 (95% CI 0.43&#x02010;4.76) compared to placebo<xref rid="apt15779-bib-0070" ref-type="ref">
<sup>70</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Methotrexate</td><td align="left" rowspan="1" colspan="1">OR 1.02 (95% 0.88&#x02010;1.19)<xref rid="apt15779-bib-0073" ref-type="ref">
<sup>73</sup>
</xref> compared with placebo</td><td align="left" rowspan="1" colspan="1">OR 0.52 (95% CI 0.04&#x02010;6.34) compared to placebo<xref rid="apt15779-bib-0073" ref-type="ref">
<sup>73</sup>
</xref>
</td></tr><tr><td align="left" colspan="3" rowspan="1">Biologic therapy</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Anti&#x02010;TNF</td><td align="left" rowspan="1" colspan="1">
<p>URTI
<list list-type="bullet" id="apt15779-list-0010"><list-item><p>Infliximab: 25% vs 9.8% placebo</p></list-item><list-item><p>Adalimumab: 16.7% vs 14.5% placebo<xref rid="apt15779-bib-0076" ref-type="ref">
<sup>76</sup>
</xref>
</p></list-item></list>
</p>
<p>LRTI compared to placebo
<list list-type="bullet" id="apt15779-list-0011"><list-item><p>OR 1.28 (95% CI: 1.08&#x02010;1.52)<xref rid="apt15779-bib-0062" ref-type="ref">
<sup>62</sup>
</xref>
</p></list-item></list>
</p>
</td><td align="left" rowspan="1" colspan="1">OR 1.43 (95% CI: 1.11&#x02010;1.84;&#x000a0;<italic>P&#x000a0;=</italic>&#x000a0;0.006) compared to placebo<xref rid="apt15779-bib-0075" ref-type="ref">
<sup>75</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Ustekinumab</td><td align="left" rowspan="1" colspan="1">
<p>URTI
<list list-type="bullet" id="apt15779-list-0012"><list-item><p>10.7% in ustekinumab 12&#x02010;weekly and 12.9% ustekinumab 8&#x02010;weekly vs 7.5% placebo<xref rid="apt15779-bib-0082" ref-type="ref">
<sup>82</sup>
</xref>
</p></list-item></list>
</p>
</td><td align="left" rowspan="1" colspan="1">4.21 (95% CI 3.25&#x02010;5.36) in ustekinumab group vs 3.97 (95% CI 2.05&#x02010;6.97) in placebo per 100 patient&#x02010;years of follow&#x02010;up<xref rid="apt15779-bib-0082" ref-type="ref">
<sup>82</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Vedolizumab</td><td align="left" rowspan="1" colspan="1">
<p>URTI compared to placebo
<list list-type="bullet" id="apt15779-list-0013"><list-item><p>HR 1.23, log&#x02010;rank&#x000a0;<italic>P =</italic>&#x000a0;.173<xref rid="apt15779-bib-0120" ref-type="ref">
<sup>120</sup>
</xref>
</p></list-item></list>
</p>
<p>LRTI compared to placebo
<list list-type="bullet" id="apt15779-list-0014"><list-item><p>HR 0.95, log&#x02010;rank&#x000a0;<italic>P&#x000a0;=</italic>&#x000a0;0.851<xref rid="apt15779-bib-0120" ref-type="ref">
<sup>120</sup>
</xref>
</p></list-item></list>
</p>
</td><td align="left" rowspan="1" colspan="1">4.3/100 patient&#x02010;years (95% CI 3.7&#x02010;4.9) vs 3.8/100 patient&#x02010;years (95% CI 1.2&#x02010;6.4) for placebo <xref rid="apt15779-bib-0086" ref-type="ref">
<sup>86</sup>
</xref>
</td></tr><tr><td align="left" colspan="3" rowspan="1">Small molecule therapy</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Tofacitinib 5&#x000a0;mg</td><td align="left" rowspan="1" colspan="1">
<p>URTI
<list list-type="bullet" id="apt15779-list-0015"><list-item><p>4.5% sv 3.3% with placebo in RA patients<xref rid="apt15779-bib-0121" ref-type="ref">
<sup>121</sup>
</xref>
</p></list-item></list>
</p>
<p>Nasopharyngitis 10% vs 2.8% placebo<xref rid="apt15779-bib-0122" ref-type="ref">
<sup>122</sup>
</xref>
</p>
</td><td align="left" rowspan="1" colspan="1">2.3 (95% CI: 1.8 to 2.8) /100 patient&#x02010;years (in RA)<xref rid="apt15779-bib-0123" ref-type="ref">
<sup>123</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Tofacitinib 10&#x000a0;mg</td><td align="left" rowspan="1" colspan="1">
<p>URTI
<list list-type="bullet" id="apt15779-list-0016"><list-item><p>6% vs 4% with placebo in UC patients<xref rid="apt15779-bib-0122" ref-type="ref">
<sup>122</sup>
</xref>
</p></list-item></list>
</p>
<p>Nasopharyngitis 14% vs 2.8% placebo<xref rid="apt15779-bib-0122" ref-type="ref">
<sup>122</sup>
</xref>
</p>
</td><td align="left" rowspan="1" colspan="1">2.7 (95% CI: 2.3 to 3.1)/100 patient&#x02010;years (in RA)<xref rid="apt15779-bib-0123" ref-type="ref">
<sup>123</sup>
</xref>
</td></tr></tbody></table><table-wrap-foot id="apt15779-ntgp-0002"><fn id="apt15779-note-0003"><p>Abbreviations: HR, hazard ratio; LRTI, lower respiratory tract infection; OR, odds ratio; RA, rheumatoid arthritis; CI, confidence interval; RR, relative risk; URTI, upper respiratory tract infection.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions></table-wrap><p>Overall, apart from corticosteroids, the risks of IBD therapies, particularly 5&#x02010;ASAs and biologics, appear limited, and the importance of careful discussion regarding the risks versus benefits of medications with patients and among medical practitioners cannot be overstated. Inappropriate cessation of effective agents due to unjustified fear of adverse events may lead to IBD relapse, which when requiring the use of steroids or hospitalisation may inadvertently strain medical resources and increase the risk of COVID&#x02010;19 exposure and infection.</p><sec id="apt15779-sec-0016"><label>4.1</label><title>Sulfasalazine and 5&#x02010;aminosalicylates (5&#x02010;ASAs)</title><p>Sulfasalazine and the 5&#x02010;ASA medications are used as first&#x02010;line induction and maintenance treatment for UC. 5&#x02010;ASAs have very mild immunosuppressive activity and they are often well tolerated with minimal side effects. There are no reports of these medications being associated with an increased risk of infection and studies of large cohorts evaluating the safety profile of 5&#x02010;ASAs do not demonstrate an increased risk of serious or opportunistic infections.<xref rid="apt15779-bib-0053" ref-type="ref">
<sup>53</sup>
</xref>
<boxed-text position="anchor" content-type="box" id="apt15779-blkfxd-0001" orientation="portrait"><p>
<bold>Sulfasalazine and 5&#x02010;ASA</bold>
<list list-type="bullet" id="apt15779-list-0001"><list-item><p>Treatment with 5&#x02010;ASA therapy should continue without concern for increased risk of contracting or developing severe COVID&#x02010;19.</p></list-item><list-item><p>If a patient is in contact with someone who has COVID&#x02010;19 or develops COVID&#x02010;19, treatment with 5&#x02010;ASA should continue.</p></list-item></list>
</p></boxed-text>
</p></sec><sec id="apt15779-sec-0017"><label>4.2</label><title>Corticosteroids</title><p>Corticosteroids systemically reduce inflammation by turning off multiple inflammatory genes. In patients with COVID&#x02010;19, a systemic inflammatory response syndrome can perpetuate lung injury with persistent inflammation resulting in ongoing pulmonary damage even subsequent to viral suppression.<xref rid="apt15779-bib-0054" ref-type="ref">
<sup>54</sup>
</xref> Corticosteroids have therefore been trialled in the treatment of coronavirus&#x02019;, including COVID&#x02010;19.<xref rid="apt15779-bib-0054" ref-type="ref">
<sup>54</sup>
</xref>, <xref rid="apt15779-bib-0055" ref-type="ref">
<sup>55</sup>
</xref>, <xref rid="apt15779-bib-0056" ref-type="ref">
<sup>56</sup>
</xref> However corticosteroids in these infections have no demonstrated benefit; rather, steroids have been shown to increase harm in the management of SARS,<xref rid="apt15779-bib-0054" ref-type="ref">
<sup>54</sup>
</xref> MERS<xref rid="apt15779-bib-0055" ref-type="ref">
<sup>55</sup>
</xref> and influenza.<xref rid="apt15779-bib-0056" ref-type="ref">
<sup>56</sup>
</xref> In a retrospective observational study of 309 patients who were critically ill with MERS, the 159 patients who received corticosteroids were more likely to require mechanical ventilation, vasopressors and renal replacement therapy.<xref rid="apt15779-bib-0055" ref-type="ref">
<sup>55</sup>
</xref> Furthermore, corticosteroids were not associated with a difference in 90&#x02010;day mortality (adjusted odds ratio 0.8, 95% CI: 0.5&#x02010;1.1, <italic>P</italic>&#x000a0;=&#x000a0;0.12) but were associated with delayed clearance of viral RNA from respiratory tract secretions (adjusted hazard ratio 0.4, 95% CI 0.2&#x02010;0.7; <italic>P</italic>&#x000a0;=&#x000a0;0.0005).<xref rid="apt15779-bib-0055" ref-type="ref">
<sup>55</sup>
</xref> In SARS, corticosteroid treatment was of no clinical benefit in regard to infection resolution but was associated with an increased risk of psychosis,<xref rid="apt15779-bib-0057" ref-type="ref">
<sup>57</sup>
</xref> delayed clearance of viral RNA,<xref rid="apt15779-bib-0058" ref-type="ref">
<sup>58</sup>
</xref> diabetes<xref rid="apt15779-bib-0059" ref-type="ref">
<sup>59</sup>
</xref> and avascular necrosis.<xref rid="apt15779-bib-0060" ref-type="ref">
<sup>60</sup>
</xref> Finally, in a systematic review on corticosteroid treatment in influenza patients, corticosteroids were associated with an increased length of stay in intensive care, an increased rate of secondary bacterial and fungal infections and an increase in mortality compared to those who did not receive corticosteroids.<xref rid="apt15779-bib-0056" ref-type="ref">
<sup>56</sup>
</xref> Whether this indicates that those already on steroids for management of other medical illnesses are at increased risk of adverse outcomes with COVID&#x02010;19 remains uncertain; however, steroids are widely known to increase the risk of opportunistic infections and respiratory infections including influenza, pneumonia and severe infections and are associated with an increased risk of hospitalisation and mortality in IBD patients, particularly at doses of prednisolone or its equivalent &#x02265;20&#x000a0;mg.<xref rid="apt15779-bib-0061" ref-type="ref">
<sup>61</sup>
</xref>, <xref rid="apt15779-bib-0062" ref-type="ref">
<sup>62</sup>
</xref>, <xref rid="apt15779-bib-0063" ref-type="ref">
<sup>63</sup>
</xref>, <xref rid="apt15779-bib-0064" ref-type="ref">
<sup>64</sup>
</xref> Therefore, due to the possible risks with systemic corticosteroids, IBD patients should taper their systemic corticosteroids to the lowest tolerated dose with complete weaning where possible. Patients should also be advised not to self&#x02010;commence systemic corticosteroids to control IBD symptoms unless under the direction of their gastroenterologist. Where possible if patients come into contact with a COVID&#x02010;19 patient or develop COVID&#x02010;19 symptoms they should also taper corticosteroids.</p><p>Data for budesonide and beclomethasone, locally acting corticosteroids with low systemic bioavailability, demonstrate that these medications are associated with significantly fewer side effects when compared to systemic corticosteroids with adverse events similar to placebo.<xref rid="apt15779-bib-0065" ref-type="ref">
<sup>65</sup>
</xref>, <xref rid="apt15779-bib-0066" ref-type="ref">
<sup>66</sup>
</xref>, <xref rid="apt15779-bib-0067" ref-type="ref">
<sup>67</sup>
</xref>, <xref rid="apt15779-bib-0068" ref-type="ref">
<sup>68</sup>
</xref>, <xref rid="apt15779-bib-0069" ref-type="ref">
<sup>69</sup>
</xref>
<boxed-text position="anchor" content-type="box" id="apt15779-blkfxd-0002" orientation="portrait"><p>
<bold>Corticosteroids</bold>
<list list-type="bullet" id="apt15779-list-0002"><list-item><p>Corticosteroids (particularly &#x02265;20&#x000a0;mg prednisolone or its equivalent) are associated with an increased risk of infection; however, it is unclear if treatment with corticosteroids is associated with an increased risk of COVID&#x02010;19 infection or complications.</p></list-item><list-item><p>Where possible, corticosteroid use should be avoided and rapid tapering should be considered&#x000a0;&#x000b1;&#x000a0;switch to budesonide. This must be weighed up against the risk of IBD flare.</p></list-item><list-item><p>If a patient requires a course of corticosteroids to treat a flare, consider the use of budesonide or beclomethasone where possible, and in CD, consider exclusive enteral nutrition (EEN) as an alternative induction agent.</p></list-item><list-item><p>If a patient is in contact with a person with COVID&#x02010;19 or develops COVID&#x02010;19, taper corticosteroids&#x000a0;&#x000b1;&#x000a0;switch to budesonide or beclomethasone where possible, but consider need for stress&#x02010;dose steroids if septic or shocked.</p></list-item></list>
</p></boxed-text>
</p></sec><sec id="apt15779-sec-0018"><label>4.3</label><title>Immunomodulators</title><p>Immunomodulators are commonly used in the management of IBD, as monotherapy or combination therapy, with a view to maintaining remission in isolation or enhancing the pharmacologic profile of the biologics. These agents, previously used predominantly in the chemotherapy and transplant setting, act to alter immune function by causing apoptosis of T cells, integral in host defence against viral pathogens.<xref rid="apt15779-bib-0070" ref-type="ref">
<sup>70</sup>
</xref> Thiopurines (azathioprine and mercaptopurine) have been associated with an increased risk of serious and opportunistic infections<xref rid="apt15779-bib-0070" ref-type="ref">
<sup>70</sup>
</xref> and appear to reduce immune response to viruses, with their use being associated with up to a fivefold increased risk of herpes simplex virus lesions and significant worsening of viral warts.<xref rid="apt15779-bib-0071" ref-type="ref">
<sup>71</sup>
</xref> However there is limited evidence that they increase the risk of either upper respiratory tract infections or pulmonary infections.<xref rid="apt15779-bib-0070" ref-type="ref">
<sup>70</sup>
</xref>, <xref rid="apt15779-bib-0071" ref-type="ref">
<sup>71</sup>
</xref> In addition, mercaptopurine has been shown to inhibit one of the proteases essential to viral maturation of MERS&#x02010;CoV in vitro, although no further animal&#x02010;based models exist to suggest clinical efficacy.<xref rid="apt15779-bib-0072" ref-type="ref">
<sup>72</sup>
</xref>
</p><p>Methotrexate has variably been demonstrated to increase the risk of infections in patients with inflammatory diseases. Reassuringly, a recent systematic review reassuringly found that in the nonrheumatoid arthritis inflammatory disease population, there was not an increased risk of infection with methotrexate (1.03, 95% CI0.82&#x02010;1.3).<xref rid="apt15779-bib-0073" ref-type="ref">
<sup>73</sup>
</xref> This applied similarly to respiratory infections specifically.<xref rid="apt15779-bib-0074" ref-type="ref">
<sup>74</sup>
</xref>
<boxed-text position="anchor" content-type="box" id="apt15779-blkfxd-0003" orientation="portrait"><p>
<bold>Immunomodulators</bold>
<list list-type="bullet" id="apt15779-list-0003"><list-item><p>No clear evidence of increased risk of lower respiratory tract infections with immunomodulators</p></list-item><list-item><p>Some evidence that thiopurines impair viral immunity and mixed evidence that that they have some anti&#x02010;viral activity.</p></list-item><list-item><p>Weigh risks and benefits, but most patients can continue on stable dose. In older patients, those in sustained remission and with co&#x02010;morbidities, consider ceasing.</p></list-item><list-item><p>Avoid commencing thiopurines or increasing dose: this will allow patients to avoid potential side effects and frequent pathology monitoring.</p></list-item><list-item><p>If a patient is in contact with someone with COVID&#x02010;19 consider temporarily withholding thiopurines for 2&#x000a0;weeks.</p></list-item><list-item><p>If a patient tests positive for SARS&#x02010;CoV&#x02010;2 and/or develops COVID&#x02010;19, consider temporarily withholding thiopurines until patient clears infection.</p></list-item></list>
</p></boxed-text>
</p></sec><sec id="apt15779-sec-0019"><label>4.4</label><title>Biologics</title><sec id="apt15779-sec-0020"><label>4.4.1</label><title>TNF antagonists</title><p>Anti&#x02010;TNF agents have been shown to increase the risk of upper and lower respiratory tract infections, as well as serious and opportunistic pulmonary infections.<xref rid="apt15779-bib-0062" ref-type="ref">
<sup>62</sup>
</xref>, <xref rid="apt15779-bib-0075" ref-type="ref">
<sup>75</sup>
</xref>, <xref rid="apt15779-bib-0076" ref-type="ref">
<sup>76</sup>
</xref> Compared with anti&#x02010;TNF monotherapy, risk of serious infections increases with combination of anti&#x02010;TNF and an immunosuppressive agent or most significantly in combination with corticosteroids.<xref rid="apt15779-bib-0077" ref-type="ref">
<sup>77</sup>
</xref> In a study that did not separate mono&#x02014;or combination&#x02014;anti&#x02010;TNF therapies, the risk of pneumonia was only slightly increased in patients receiving a TNF antagonist (OR: 1.28, 95% CI [1.08&#x02010;1.52]).<xref rid="apt15779-bib-0062" ref-type="ref">
<sup>62</sup>
</xref>
</p><p>Of note, anti&#x02010;TNF therapy has been employed in the management of severe sepsis, with a meta&#x02010;analysis demonstrating reduced overall mortality when used in severe sepsis before shock, and improved survival at 30&#x000a0;days in patients with shock or high baseline levels of IL&#x02010;6.<xref rid="apt15779-bib-0078" ref-type="ref">
<sup>78</sup>
</xref> There are no data on the incidence and severity of SARS or COVID&#x02010;19 in patients on anti&#x02010;TNF medications. Anti&#x02010;TNF agents were utilised in the initial phase of the SARs epidemic, although the overall evidence for efficacy is lacking.<xref rid="apt15779-bib-0079" ref-type="ref">
<sup>79</sup>
</xref>
</p></sec><sec id="apt15779-sec-0021"><label>4.4.2</label><title>Biologics: non&#x02010;TNF antagonists</title><p>The main non&#x02010;TNF antagonist biologics for IBD include the anti&#x02010;IL12/23 biologic ustekinumab and the anti&#x02010;integrin therapy, vedolizumab. Reassuringly, the risk of severe respiratory tract infections, severe infections in general or opportunistic infections does not appear to be increased in long&#x02010;term follow&#x02010;up studies of ustekinumab in both IBD and psoriasis.<xref rid="apt15779-bib-0080" ref-type="ref">
<sup>80</sup>
</xref>, <xref rid="apt15779-bib-0081" ref-type="ref">
<sup>81</sup>
</xref>, <xref rid="apt15779-bib-0082" ref-type="ref">
<sup>82</sup>
</xref> Similar data have also been reported for vedolizumab.<xref rid="apt15779-bib-0083" ref-type="ref">
<sup>83</sup>
</xref>, <xref rid="apt15779-bib-0084" ref-type="ref">
<sup>84</sup>
</xref>, <xref rid="apt15779-bib-0085" ref-type="ref">
<sup>85</sup>
</xref>, <xref rid="apt15779-bib-0086" ref-type="ref">
<sup>86</sup>
</xref> There is a theoretical concern of an increased risk of respiratory infections, and hence COVID&#x02010;19, with vedolizumab treatment as vedolizumab binds the T&#x02010;cell integrin receptor &#x003b1;<sub>4</sub>&#x003b2;<sub>7,</sub> inhibiting its binding to MADCAM1 present on the small intestinal endothelium and vasculature. These receptors are also expressed in the T cells occupying the nares, although to a far lesser extent when compared to the intestine.<xref rid="apt15779-bib-0087" ref-type="ref">
<sup>87</sup>
</xref> Reassuringly, a recently conducted network meta&#x02010;analysis failed to demonstrate a significant difference in rates of nasopharyngitis between anti&#x02010;TNF agents and vedolizumab, and multiple studies on the safety of vedolizumab have demonstrated that there is no increased risk of respiratory, systemic or serious infections in patients on vedolizumab over placebo .<xref rid="apt15779-bib-0083" ref-type="ref">
<sup>83</sup>
</xref>, <xref rid="apt15779-bib-0084" ref-type="ref">
<sup>84</sup>
</xref>, <xref rid="apt15779-bib-0085" ref-type="ref">
<sup>85</sup>
</xref>, <xref rid="apt15779-bib-0086" ref-type="ref">
<sup>86</sup>
</xref>
<boxed-text position="anchor" content-type="box" id="apt15779-blkfxd-0004" orientation="portrait"><p>
<bold>Biological therapies</bold>
<list list-type="bullet" id="apt15779-list-0004"><list-item><p>Biological therapies appear relatively safe.</p></list-item><list-item><p>If commencing&#x000a0;on a new patient, where appropriate consider subcutaneous dosing mechanism to reduce infusion centre burden/health facility contact.</p></list-item><list-item><p>Elective switching from infliximab infusions to subcutaneous anti&#x02010;TNF formulations is not advised as&#x000a0;this may increase the risk of relapse.<xref rid="apt15779-bib-0088" ref-type="ref">
<sup>88</sup>
</xref>
</p></list-item><list-item><p>If on combination therapy and patient is in deep remission and/or older, consider withholding/ceasing immunomodulator therapy to reduce infection risk. If possible utilise therapeutic drug monitoring to guide decision.</p></list-item><list-item><p>If patient is in contact with someone who has COVID&#x02010;19, consider withholding anti&#x02010;TNF therapies for 2&#x000a0;weeks. Likely safe to continue other biologics.</p></list-item><list-item><p>If patient tests positive for SARS&#x02010;CoV&#x02010;2 and/or develops COVID&#x02010;19, consider withholding biologics until patient clears infection.</p></list-item></list>
</p></boxed-text>
</p></sec></sec><sec id="apt15779-sec-0022"><label>4.5</label><title>JAK inhibitors</title><p>Tofacitinib, an orally active Janus kinase (JAK) inhibitor, is employed in the management of UC, particularly in those patients with disease refractory to biologic agents. Tofacitinib may impair immunity to viral infections and has been shown to increase the risk of herpes zoster (HZ) infection, with 5.6% of UC patients developing HZ on long&#x02010;term extension trials.<xref rid="apt15779-bib-0089" ref-type="ref">
<sup>89</sup>
</xref> However, long&#x02010;term follow&#x02010;up of patients treated with this agent for rheumatoid arthritis have described rates of URTI (18.8%) and nasopharyngitis (14.6%) comparable to that of anti&#x02010;TNFs.<xref rid="apt15779-bib-0090" ref-type="ref">
<sup>90</sup>
</xref> Serious infection was found to be increased with tofacitinib in the induction trials for UC, but similar across treatment groups including placebo in the maintenance trial.<xref rid="apt15779-bib-0091" ref-type="ref">
<sup>91</sup>
</xref> Of 4789 patients treated with tofacitinib in phase II, III and LTE studies, 259 patients had serious infections (3.09 events per 100 PY [95% CI 2.73, 3.49]), and the most common infection was pneumonia.<xref rid="apt15779-bib-0092" ref-type="ref">
<sup>92</sup>
</xref> Higher doses of 10&#x000a0;mg twice daily as opposed to 5&#x000a0;mg twice daily, age &#x0003e;65&#x000a0;years, corticosteroids &#x0003e;7.5&#x000a0;mg/d and diabetes were also independent factors associated with increased serious infection risk.<xref rid="apt15779-bib-0092" ref-type="ref">
<sup>92</sup>
</xref>, <xref rid="apt15779-bib-0093" ref-type="ref">
<sup>93</sup>
</xref> Therefore, patients on tofacitinib should be maintained on the lower 5&#x000a0;mg twice daily dose compared to 10&#x000a0;mg twice daily where possible and weaned off corticosteroids.</p><p>Interestingly, baricitinib, a JAK inhibitor used in rheumatoid arthritis, has a potential therapeutic role in the management of SARS&#x02010;CoV&#x02010;2 through both its anti&#x02010;inflammatory action and Numb&#x02010;associated kinase (NAK) inhibition. Tofacitinib has no affinity for this particular kinase. NAKs are involved in the function of clathrin, which mediates endocytosis of SARS&#x02010;CoV&#x02010;2 into cells resulting in infection.<xref rid="apt15779-bib-0094" ref-type="ref">
<sup>94</sup>
</xref> Due to the anti&#x02010;inflammatory effects of the JAK inhibitors, it has also been speculated that they may be able to combat the elevated levels of cytokines observed in COVID&#x02010;19 which may potentially further decrease the severity of the infection.<xref rid="apt15779-bib-0094" ref-type="ref">
<sup>94</sup>
</xref>
<boxed-text position="anchor" content-type="box" id="apt15779-blkfxd-0005" orientation="portrait"><p>
<bold>JAK inhibitors</bold>
<list list-type="bullet" id="apt15779-list-0005"><list-item><p>JAK inhibitors may impair viral immunity.</p></list-item><list-item><p>Use lowest effective dose to maintain remission: Where possible maintain patients on 5&#x000a0;mg twice daily as opposed to 10&#x000a0;mg twice daily.</p></list-item><list-item><p>Avoid commencing tofacitinib during pandemic unless there are no other alternatives. This will allow patients to avoid potential side effects and frequent pathology monitoring.</p></list-item><list-item><p>If a patient is in contact with someone with COVID&#x02010;19, consider temporarily withholding tofacitinib for 2&#x000a0;weeks.</p></list-item><list-item><p>If a patient tests positive for SARS&#x02010;CoV&#x02010;2 and/or develops COVID&#x02010;19, consider withholding tofacitinib until patient clears the infection.</p></list-item></list>
</p></boxed-text>
</p></sec><sec id="apt15779-sec-0023"><label>4.6</label><title>Recommencement of medications following COVID&#x02010;19 infection</title><p>If a patient is exposed to or gets infected with COVID&#x02010;19, the withholding of immunosuppressive medications should be considered where possible. Patients exposed to COVID&#x02010;19 will usually display symptoms of COVID&#x02010;19 within 14&#x000a0;days and therefore if they remain asymptomatic, recommencement of these medications can occur at this time point. If a patient develops COVID&#x02010;19 and has held/delayed their IBD medication, recommencement of medication can occur once the infection has been cleared.</p><p>To clear a patient of COVID&#x02010;19:
<list list-type="order" id="apt15779-list-0006"><list-item><p>Where testing is available: patients can be cleared of COVID&#x02010;19 if they have clinically recovered and have two negative nasopharyngeal swabs at 24&#x000a0;hour intervals at least 8&#x000a0;days after symptom onset.<xref rid="apt15779-bib-0095" ref-type="ref">
<sup>95</sup>
</xref>
</p></list-item><list-item><p>Where testing capacity is limited: due to potential prolonged shedding, guidelines suggest an immunocompromised patient should wait at LEAST 14&#x000a0;days after symptom onset (as opposed to 8&#x000a0;days in non&#x02010;immunocompromised patients) and be cleared if there is clinical improvement in symptoms and complete resolution of fever for at LEAST 3&#x000a0;days.<xref rid="apt15779-bib-0095" ref-type="ref">
<sup>95</sup>
</xref>
</p></list-item></list>
</p><p>It is important to note that many IBD medications may take months to be eliminated from the body so the utility of withholding these medications in the short term is likely to be limited. (See Table <xref rid="apt15779-tbl-0003" ref-type="table">3</xref>).</p><table-wrap id="apt15779-tbl-0003" xml:lang="en" content-type="Table" orientation="portrait" position="float"><label>Table 3</label><caption><p>Half&#x02010;life elimination of IBD medications</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Drug</th><th align="left" valign="top" rowspan="1" colspan="1">Half&#x02010;life and time to reach therapeutic effect</th><th align="left" valign="top" rowspan="1" colspan="1">Elimination half&#x02010;life (Most drugs considered to have negligible effect after four&#x02010;to&#x02010;five half&#x02010;lives)</th><th align="left" valign="top" rowspan="1" colspan="1">
<p>How long the immunosuppression lasts</p>
<p>50% drug eliminated after one elimination half&#x02010;lives</p>
<p>75% drug eliminated after two elimination half&#x02010;lives</p>
<p>99% drug eliminated after seven elimination half&#x02010;lives</p>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Thiopurines (Azathioprine and Mercaptopurine)</td><td align="left" rowspan="1" colspan="1">
<p>
<italic>t</italic>
<sub>1/2</sub>:6&#x02010;TGN and 6&#x02010;MMP in RBC&#x000a0;=&#x000a0;5 days<xref rid="apt15779-bib-0124" ref-type="ref">
<sup>124</sup>
</xref>
</p>
<p>Steady state: 6&#x02010;TGN and 6&#x02010;MMP&#x000a0;=&#x000a0;4&#x000a0;weeks in RBC<xref rid="apt15779-bib-0124" ref-type="ref">
<sup>124</sup>
</xref>
</p>
<p>Median time to clinical response: 4.5 months<xref rid="apt15779-bib-0125" ref-type="ref">
<sup>125</sup>
</xref>
</p>
</td><td align="left" rowspan="1" colspan="1">6&#x02010;TGN in RBC: 6.8&#x000a0;days [IQR 5.9&#x02010;8.4&#x000a0;days]<xref rid="apt15779-bib-0126" ref-type="ref">
<sup>126</sup>
</xref>, <xref ref-type="fn" rid="apt15779-note-0004">
<sup>a</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">
<p>75% of 6&#x02010;TGN eliminated after 10&#x02010;14&#x000a0;days and expected to be negligible by day 40.<xref rid="apt15779-bib-0126" ref-type="ref">
<sup>126</sup>
</xref>
</p>
<p>Immune reconstitution occurs quickly after thiopurine cessation, if the antigen was not encountered whilst on the thiopurine therapy.<xref rid="apt15779-bib-0126" ref-type="ref">
<sup>126</sup>
</xref>
</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Adalimumab</td><td align="left" rowspan="1" colspan="1">The subcutaneous injection has a bioavailability of 64% and peak drug concentration at day 5 following injection<xref rid="apt15779-bib-0127" ref-type="ref">
<sup>127</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">
<p>17.8&#x02010;23.9&#x000a0;days (in RA population)<xref rid="apt15779-bib-0128" ref-type="ref">
<sup>128</sup>
</xref>
</p>
<p>Clearance of 0.33L/day<xref rid="apt15779-bib-0013" ref-type="ref">
<sup>13</sup>
</xref>
</p>
</td><td align="left" rowspan="1" colspan="1">75% eliminated after approximately 40&#x000a0;days</td></tr><tr><td align="left" rowspan="1" colspan="1">Infliximab</td><td align="left" rowspan="1" colspan="1">IV infusion 8&#x02010;9.5&#x000a0;days</td><td align="left" rowspan="1" colspan="1">7&#x02010;12&#x000a0;days <xref rid="apt15779-bib-0129" ref-type="ref">
<sup>129</sup>
</xref>, <xref rid="apt15779-bib-0130" ref-type="ref">
<sup>130</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">
<p>75% eliminated after 2&#x02010;3&#x000a0;weeks</p>
<p>Low volume of distribution (3&#x02010;6L/kg) and very low systemic clearance of 11&#x02010;15ml/hr, mean infliximab is predominantly in the intravascular space for 12&#x02010;17&#x000a0;days prior to elimination<xref rid="apt15779-bib-0129" ref-type="ref">
<sup>129</sup>
</xref>, <xref rid="apt15779-bib-0130" ref-type="ref">
<sup>130</sup>
</xref>
</p>
<p>Low albumin and higher body weight will speed up elimination<xref rid="apt15779-bib-0131" ref-type="ref">
<sup>131</sup>
</xref>
</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Tofacitinib</td><td align="left" rowspan="1" colspan="1">3&#x02010;3.8&#x000a0;hours</td><td align="left" rowspan="1" colspan="1">3&#x000a0;hours</td><td align="left" rowspan="1" colspan="1">
<p>After a single dose, 95% is expected to be eliminated within 24&#x000a0;hours.</p>
<p>Pharmacodynamic effects generally reversible in 14&#x000a0;days after discontinuation</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Methotrexate</td><td align="left" rowspan="1" colspan="1">Methotrexate in serum has a half&#x02010;life of 6&#x000a0;hours but is converted quickly to methotrexate polyglutamate which is stored for much longer in liver and erythrocytes.<xref rid="apt15779-bib-0132" ref-type="ref">
<sup>132</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">3&#x02010;10&#x000a0;hours (for methotrexate, not activity)</td><td align="left" rowspan="1" colspan="1">75% of methotrexate eliminated by within 24&#x000a0;hours but effect continues through active metabolites.</td></tr><tr><td align="left" rowspan="1" colspan="1">Ustekinumab</td><td align="left" rowspan="1" colspan="1">First dose given IV to reach peak concentration</td><td align="left" rowspan="1" colspan="1">19&#x000a0;days</td><td align="left" rowspan="1" colspan="1">
<p>Eliminated at 0.19 L/day (IBD)</p>
<p>75% eliminated by 38&#x000a0;days</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Golimumab</td><td align="left" rowspan="1" colspan="1">2&#x02010;2.3&#x000a0;days (RA Populations) <xref rid="apt15779-bib-0128" ref-type="ref">
<sup>128</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">14&#x000a0;days</td><td align="left" rowspan="1" colspan="1">
<p>Clearance 7.6&#x000a0;mL/kg/kg</p>
<p>75% eliminated by approx. 30&#x000a0;days</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Vedolizumab</td><td align="left" rowspan="1" colspan="1">Although given intravenously, clinical effect can takes weeks</td><td align="left" rowspan="1" colspan="1">25&#x000a0;days</td><td align="left" rowspan="1" colspan="1">
<p>Cleared at 0.157 L/day</p>
<p>75% eliminated by 50&#x000a0;days</p>
</td></tr></tbody></table><table-wrap-foot id="apt15779-ntgp-0003"><fn id="apt15779-note-0004"><label><sup>a</sup></label><p>Low numbers, n&#x000a0;=&#x000a0;9 with missing data.<xref rid="apt15779-bib-0126" ref-type="ref">
<sup>126</sup>
</xref>
</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions></table-wrap></sec></sec><sec id="apt15779-sec-0024"><label>5</label><title>NONPHARMACOLOGICAL RECOMMENDATIONS</title><p>The response to COVID&#x02010;19 is rapidly evolving and gastroenterologists should regularly review local, institutional and international recommendations. Despite limited data, patients with IBD are theoretically at increased risk of COVID&#x02010;19 due to proximity to medical facilities and immunosuppression. There are therefore several recommendations that clinics and patients can implement to reduce risks.
<list list-type="order" id="apt15779-list-0007"><list-item><p>
<italic>Optimise health and treat malnutrition:</italic> Nutrition should be optimised as malnutrition can disrupt the innate immune response, including complement and mucosal secretory antibody formation, and is associated with increased infection risk in IBD patients.<xref rid="apt15779-bib-0096" ref-type="ref">
<sup>96</sup>
</xref> Smoking has been associated with worse outcomes and increased mortality in COVID&#x02010;19<xref rid="apt15779-bib-0017" ref-type="ref">
<sup>17</sup>
</xref> and therefore patients should be encouraged to quit smoking.</p></list-item><list-item><p>
<italic>Immunisation:</italic> Immunisation of patients should be strongly encouraged to reduce preventable co&#x02010;infection with other viruses: Patients should receive pneumococcus (PCV13 and PPSV 23) and influenza (quadrivalent inactivated vaccine) vaccination.</p></list-item><list-item><p>
<italic>Reduce transmission:</italic> SARS&#x02010;CoV&#x02010;2 undergoes human&#x02010;to&#x02010;human transmission and strategies to reduce transmission should be instigated in populations at risk.<xref rid="apt15779-bib-0028" ref-type="ref">
<sup>28</sup>
</xref> Patients should wash hands with soap and water for 20&#x000a0;seconds or use an alcohol rub, practice social distancing by working from home, standing 2&#x000a0;m apart from people, avoid touching nose, eyes and mouth and avoiding non&#x02010;essential travel. <xref rid="apt15779-bib-0097" ref-type="ref">
<sup>97</sup>
</xref>, <xref rid="apt15779-bib-0098" ref-type="ref">
<sup>98</sup>
</xref>
</p></list-item><list-item><p>
<italic>Avoid healthcare facilities:</italic> A large proportion of healthcare workers have been infected with SARS&#x02010;CoV&#x02010;2. Hence, it must be anticipated that super spreading within hospitals may occur.<xref rid="apt15779-bib-0028" ref-type="ref">
<sup>28</sup>
</xref> Therefore, patients should preferably avoid hospitals and medical facilities. Suitable patients should have appointments via telehealth allowing for reduced exposure of patients and staff alike to COVID&#x02010;19.<xref rid="apt15779-bib-0099" ref-type="ref">
<sup>99</sup>
</xref> Doctors should attempt to limit non&#x02010;urgent pathology requests and avoid commencing thiopurines or tofacitinib that require frequent blood monitoring early on. Finally, elective surgery and endoscopy should be postponed. Only urgent endoscopic procedures should occur and if patients require a procedure they should have prior screening for COVID&#x02010;19 if symptomatic. In addition, to limit pharmacy visits and travel on public transport, prescriptions can be changed to a 3&#x02010;month supply or patients can arrange to have medications delivered by post depending on what is available in their local area.</p></list-item><list-item><p>
<italic>Infusion centre management: </italic>To reduce the risk of transmission within the infusion centre, patients who are presenting for infusions should be contacted 1&#x02010;2 days prior to determine their risk of COVID&#x02010;19. This should include screening for COVID&#x02010;19 symptoms, confirming no direct contact with a confirmed COVID&#x02010;19 case and asking about flu&#x02010;like symptoms. If they have any risk factor, the infusion should be delayed. On attendance, patients should be re&#x02010;screened for symptoms and have their temperature checked. Alternate entry points for infusion patients to avoid contact with hospitalised patients should be arranged or where possible the infusion centre can be moved to a &#x02018;clean&#x02019; COVID&#x02010;19 free area. In addition, social distancing between patients chairs should occur and a single nurse per patient arranged to prevent infection spread. Finally, where possible, infliximab infusions should be converted to a 30&#x02010;minute protocol where safe to do so to limit the duration patients are in the infusion centre.<xref rid="apt15779-bib-0100" ref-type="ref">
<sup>100</sup>
</xref>
</p></list-item></list>
</p></sec><sec id="apt15779-sec-0025"><label>6</label><title>PHARMACOLOGICAL MANAGEMENT OF COVID&#x02010;19 IN THE IBD PATIENT</title><p>Although there does not appear to be an increased risk of COVID&#x02010;19 in patients with IBD, when an IBD patient does develop COVID&#x02010;19, there are no therapeutic options approved for the treatment of coronaviruses. Management of COVID&#x02010;19 predominantly focuses on supportive care and treating secondary complications.</p><p>The highly pathogenic nature of COVID&#x02010;19 and the need to reduce burden on the health care systems worldwide has encouraged clinicians to examine all possible treatment options. WHO has created a master protocol for a multicentre, adaptive, randomised, double blind placebo controlled trial of the safety and efficacy of investigative therapies for the treatment of COVID&#x02010;19.<xref rid="apt15779-bib-0101" ref-type="ref">
<sup>101</sup>
</xref> There are many drug trials currently occurring. Evidence behind some of these trials is discussed and possible drug interactions with IBD medications and the most commonly cited experimental COVID&#x02010;19 therapies are summarised in Table&#x000a0;<xref rid="apt15779-tbl-0004" ref-type="table">4</xref>. Where interactions exist, it is possible for patients to cease their IBD medications and continue on trial medications.</p><table-wrap id="apt15779-tbl-0004" xml:lang="en" content-type="Table" orientation="portrait" position="float"><label>Table 4A</label><caption><p>COVID&#x02010;19 experimental treatments</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">COVID&#x02010;19 treatments</th><th align="left" valign="top" rowspan="1" colspan="1">
<bold>Trials</bold>
</th><th align="left" valign="top" rowspan="1" colspan="1">
<bold>Interaction potential</bold>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<p>
<bold>Remdesivir</bold>
</p>
<p>
<bold>(GS&#x02010;5734)</bold>
</p>
<p>Adults &#x02265;40&#x000a0;kg: Daily IV dose over 30&#x000a0;min. Day 1: 200&#x000a0;mg</p>
<p>Day 2&#x02010;10: 100&#x000a0;mg</p>
<p>Paed &#x0003c;40&#x000a0;kg: Daily IV dose over 30&#x000a0;min.</p>
<p>Day 1: 5&#x000a0;mg/kg</p>
<p>Day 2&#x02010;10: 2.5&#x000a0;mg/kg</p>
</td><td align="left" rowspan="1" colspan="1">
<p>ClinicalTrials.gov Identifier:</p>
<p>NCT04292730</p>
<p>NCT04302766</p>
<p>NCT04292899</p>
</td><td align="left" rowspan="1" colspan="1">
<p>
<underline underline-style="single">Substrate of</underline>: CYP2C8, CYP2D6, CYP3A4, transporters OATP1B1 and Pgp
<list list-type="simple" id="apt15779-list-0030"><list-item><label>&#x02010;</label><p>
<bold><italic>Drugs that are strong inducers will decrease remdesivir effect</italic></bold>
</p></list-item></list>
</p>
<p>
<underline underline-style="single">Inhibits</underline>: CYP3A4, OATP1B1/3, BSEP, MRP4 and NTCP
<list list-type="simple" id="apt15779-list-0040"><list-item><label>&#x02010;</label><p>
<italic>unlikely clinically significant</italic>
</p></list-item></list>
</p>
<p>
<underline underline-style="single">Induces</underline>: CYP1A2 and CYP2B6
<list list-type="simple" id="apt15779-list-0045"><list-item><label>&#x02010;</label><p>
<italic>unlikely clinically significant</italic>
</p></list-item></list>
</p>
<p>
<italic>All in vitro data</italic>
</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>
<bold>Lopinavir/ Ritonavir (Kaltera) (400&#x000a0;mg/100&#x000a0;mg)</bold>
</p>
<p>400mg/100mg twice daily for 14 days</p>
<p>
<inline-graphic xlink:href="APT-9999-na-g004.jpg" xlink:title="image"/>
</p>
<p>
<inline-graphic xlink:href="APT-9999-na-g005.jpg" xlink:title="image"/>
</p>
<p>Crushing tablet &#x02193; absorption &#x02245; 45%<sup>133</sup>. Use oral liquid (42.4% alcohol and 15.3% propylene glycol)</p>
<p>Use compatible feeding tubes (PVC or silicone) Avoid metronidazole and disulfiram</p>
<p>Absorbed in jejunum: NG ok; NJ may &#x02193; effect</p>
</td><td align="left" rowspan="1" colspan="1">
<p>ClinicalTrials.gov Identifier:</p>
<p>NCT04276688</p>
<p>Chinese Clinical Trials Registry ID:</p>
<p>ChiCTR2000029539</p>
<p>EU Clinical Trials Register ID:</p>
<p>2020&#x02010;000936&#x02010;23</p>
</td><td align="left" rowspan="1" colspan="1">
<p>
<bold>Ritonavir/lopinavir:</bold>
</p>
<p>Lopinovir extensively metabolised by CYP3A</p>
<p>
<underline underline-style="single">Inhibitor of:</underline> CYP3A4 (potent*), P&#x02010;gp, BCPR, OATP1B1
<list list-type="simple" id="apt15779-list-0050"><list-item><label>&#x02010;</label><p>
<bold><italic>can increase concentration of drugs metabolised or substrates of these pathways</italic></bold>
</p></list-item></list>
</p>
<p>
<underline underline-style="single">Inducer of</underline>: CYP2C9, CYP2C19, glucuronidation</p>
<p>Can prolong PR interval.</p>
<p>Rare reports of 2<sup>nd</sup> and 3<sup>rd</sup> degree atrioventricular block in patients with underlying risk factors</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>
<bold>Chloroquine/Hydroxychloroquine</bold>
</p>
<p>200&#x000a0;mg three times a day for 10&#x000a0;days</p>
<p>
<inline-graphic xlink:href="APT-9999-na-g006.jpg" xlink:title="image"/>
</p>
</td><td align="left" rowspan="1" colspan="1">
<p>ClinicalTrials.gov Identifier:</p>
<p>NCT04261517</p>
<p>Chinese Clinical Trials Registry ID:</p>
<p>ChiCTR2000029609</p>
</td><td align="left" rowspan="1" colspan="1">
<p>
<underline underline-style="single">Metabolised by</underline>: CYP2C8, CYP3A4, CYP2D6</p>
<p>
<underline underline-style="single">Inhibited by:</underline> CYP2D6 and P&#x02010;gp</p>
<p>Can prolong QTc interval, consider ECG monitoring where appropriate</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Interferon beta</bold>
</td><td align="left" rowspan="1" colspan="1">
<p>ClinicalTrials.gov Identifier:</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04276688?recrs=a&#x00026;cond=COVID-19&#x00026;draw=2&#x00026;rank=47">https://clinicaltrials.gov/ct2/show/NCT04276688?recrs=a&#x00026;cond=COVID-19&#x00026;draw=2&#x00026;rank=47</ext-link>
</p>
</td><td align="left" rowspan="1" colspan="1">
<p>Interferons have been reported to reduce CYP450 drug metabolism
<list list-type="simple" id="apt15779-list-0055"><list-item><label>&#x02010;</label><p>care with narrow therapeutic index drugs dependent on CYP450 clearance</p></list-item></list>
</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>
<bold>Ribavirin</bold>
</p>
<p>
<inline-graphic xlink:href="APT-9999-na-g004.jpg" xlink:title="image"/>
</p>
<p>Do not crush &#x02013;known teratogen.</p>
<p>Contact hospital pharmacy for solution compounded from capsules or (SAS) product availability</p>
</td><td align="left" rowspan="1" colspan="1">
<p>ClinicalTrials.gov Identifier:</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04276688?recrs=a&#x00026;cond=COVID-19&#x00026;draw=2&#x00026;rank=47">https://clinicaltrials.gov/ct2/show/NCT04276688?recrs=a&#x00026;cond=COVID-19&#x00026;draw=2&#x00026;rank=47</ext-link>
</p>
</td><td align="left" rowspan="1" colspan="1">
<p>Not metabolised by CYP450 unlikely to contribute to CYP interactions.</p>
<p>Inhibits inosine monophosphate dehydrogenase:</p>
<p>Can interfere with azathioprine metabolism possibly leading to accumulation of 6&#x02010;methylthioinosine monophosphate (6&#x02010;MTIMP), which has been associated with myelotoxicity</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>
<bold>Favipiravir</bold>
</p>
<p>
<inline-graphic xlink:href="APT-9999-na-g006.jpg" xlink:title="image"/>
</p>
</td><td align="left" rowspan="1" colspan="1">
<p>Chinese Clinical Trials Registry ID:</p>
<p>ChiCTR2000029600</p>
<p>favipiravir plus interferon&#x02010;&#x003b1;</p>
<p>ChiCTR2000029544</p>
<p>favipiravir plus baloxavir marboxil</p>
</td><td align="left" rowspan="1" colspan="1">
<p>
<underline underline-style="single">Metabolised by</underline>: Nicotinamide adenine dinucleotide phosphate (NADPH) independent and dependent enzymes.</p>
<p>
<underline underline-style="single">Inhibits:</underline>
</p>
<p>CYP2C8 <italic>(strong)</italic>
</p>
<p>OAT1, OAT3 (mod)</p>
<p>CYP1A2<italic>(weak)</italic>, CYP2C9<italic>(weak)</italic>, CYP2C19<italic>(weak)</italic>, CYP2CD6<italic>(weak)</italic>, CYP2E1<italic>(weak)</italic>, CYP3A4<italic>(weak)</italic>
</p>
<p>Low risk QT prolongation</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>
<bold>Atazanavir</bold>
</p>
<p>
<inline-graphic xlink:href="APT-9999-na-g007.jpg" xlink:title="image"/>
</p>
<p>Requires pH &#x0003c;4. Avoid antacids 2&#x000a0;h before and 1 hour after.</p>
<p>Food &#x02191; bioavailability</p>
<p>Absorbed in jejunum: NG ok; NJ may &#x02193; effect</p>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>
<underline underline-style="single">Metabolised by</underline>: CYP3A4 (extensively)</p>
<p>
<underline underline-style="single">Inhibits:</underline> CYP3A4, UGT1A1, OATP1B1 (strong), CYP2C8 (weak)</p>
<p>Absorption depends on low pH; drugs increasing pH will decrease atazanavir concentration</p>
<p>Dose related prolongation in PR interval. Care with drugs increasing QT interval or in patients with pre&#x02010;existing risk factors.</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>
<bold>Nitazoxanide (prodrug)</bold>
</p>
<p>
<bold>(active metabolite: tizoxanide)</bold>
</p>
<p>
<bold>May be dispersible or crushed&#x02013; check brand</bold>
</p>
<p>Take with food &#x02010; increases bioavailability by 50%.</p>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>Nil effects on CYP450 enzymes</p>
<p>Tizoxanide highly protein bound (&#x0003e;99.9%)
<list list-type="simple" id="apt15779-list-0060"><list-item><label>&#x02010;</label><p>will compete for binding sites; monitor drugs highly protein bound with a narrow therapeutic index (ie warfarin)</p></list-item></list>
</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Tocilizumab (IL&#x02010;6 monoclonal antibody)</bold>
</td><td align="left" rowspan="1" colspan="1">
<p>ClinicalTrials.gov Identifier:</p>
<p>NCT04310228</p>
<p>NCT04306705</p>
</td><td align="left" rowspan="1" colspan="1">
<p>Nil significant drug interactions.</p>
<p>COVID&#x02010;19 increases IL&#x02010;6 expression. Tocilizumab reduces IL&#x02010;6 expression. IL&#x02010;6 increases CYP3A4, CYP26C19, CYP2C9, CYP1A2. When tocilizumab is used to treat COVID&#x02010;19, the effect on drugs effected by these CYP enzymes is unknown.</p>
</td></tr></tbody></table><table-wrap-foot id="apt15779-ntgp-0020"><fn id="apt15779-note-0020"><p>
<inline-graphic xlink:href="APT-9999-na-g006.jpg" xlink:title="image"/> Can be crushed; <inline-graphic xlink:href="APT-9999-na-g007.jpg" xlink:title="image"/> Can open capsule; <inline-graphic xlink:href="APT-9999-na-g004.jpg" xlink:title="image"/> Do not crush; <inline-graphic xlink:href="APT-9999-na-g005.jpg" xlink:title="image"/> Liquid product available.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions></table-wrap><table-wrap id="apt15779-tbl-0005" xml:lang="en" content-type="Table" orientation="portrait" position="float"><label>Table 4B</label><caption><p>Interactions with IBD medications</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">COVID&#x02010;19 treatments</th><th align="left" colspan="8" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Interactions with IBD treatments</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">
<p>
<underline underline-style="single">Corticosteroids</underline>
</p>
<p>Methylprednisolone, Prednisolone, Budesonide, Beclomethasone, Hydrocortisone*#:</p>
<p>Metabolised by CYP3A4, CYP3A5*, CYP3A7*</p>
<p>Substrate: P&#x02010;glycoprotein</p>
<p>#Not clinically relevant</p>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<p>
<underline underline-style="single">Thiopurines</underline> (azathioprine/ mercaptopurine)</p>
<p>Metabolised by: TMPT, HGPRT, XO</p>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<p>
<underline underline-style="single">Methotrexate</underline>
</p>
<p>Transported into the cell by: Reduced folate carrier 1</p>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<p>
<underline underline-style="single">Tacrolimus</underline>
</p>
<p>Inhibits: CYP3A4 (weak)</p>
<p>Metabolised by CYP3A4</p>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<p>
<underline underline-style="single">Ciclosporin</underline>
</p>
<p>Metabolised by CYP3A4</p>
<p>Inhibits: CYP3A4 (moderate),P&#x02010;glycoprotein</p>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<p>
<underline underline-style="single">Tofacitinib</underline>
</p>
<p>Metabolised by CYP3A4 (major) CYP2C19 (minor)</p>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<p>
<underline underline-style="single">5ASA</underline>
</p>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<p>
<underline underline-style="single">Biologics</underline>
</p>
<p>Adalimumab</p>
<p>Infliximab</p>
<p>Golimumab</p>
<p>Vedolizumab</p>
<p>Ustekinumab</p>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<p>
<bold>Remdesivir</bold>
</p>
<p>
<bold>(GS&#x02010;5734)</bold>
</p>
<p>Adults &#x02265;40&#x000a0;kg: Daily IV dose over 30&#x000a0;min. Day 1: 200&#x000a0;mg</p>
<p>Day 2&#x02010;10: 100&#x000a0;mg</p>
<p>Paed &#x0003c;40&#x000a0;kg: Daily IV dose over 30min.</p>
<p>Day 1: 5&#x000a0;mg/kg</p>
<p>Day 2&#x02010;10: 2.5&#x000a0;mg/kg</p>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>
<bold>Lopinavir/Ritonavir (Kaltera) (400&#x000a0;mg/100&#x000a0;mg)</bold>
</p>
<p>400&#x000a0;mg/100&#x000a0;mg twice daily for 14&#x000a0;days</p>
<p>
<inline-graphic xlink:href="APT-9999-na-g004.jpg" xlink:title="image"/>
</p>
<p>
<inline-graphic xlink:href="APT-9999-na-g005.jpg" xlink:title="image"/>
</p>
<p>Crushing tablet &#x02193; absorption &#x02245; 45%<xref rid="apt15779-bib-0133" ref-type="ref">
<sup>133</sup>
</xref>. Use oral liquid (42.4% alcohol and 15.3% propylene glycol)</p>
<p>Use compatible feeding tubes (PVC or silicone) Avoid metronidazole and disulfiram</p>
<p>Absorbed in jejunum: NG ok; NJ may &#x02193; effect</p>
</td><td align="left" rowspan="1" colspan="1">
<p>
<inline-graphic xlink:href="APT-9999-na-g002.jpg" xlink:title="image"/>
</p>
<p>&#x02191; <bold>Methylprednisolone:</bold> Consider 50% dose reduction <xref rid="apt15779-bib-0124" ref-type="ref">
<sup>124</sup>
</xref>.</p>
<p>&#x02191; <bold>Prednisolone:</bold>
</p>
<p>&#x02193; plasma cortisol (level if appropriate)</p>
<p>&#x02191; <bold>Budesonide:</bold>
</p>
<p>10&#x02010;20% absorbed<xref rid="apt15779-bib-0134" ref-type="ref">
<sup>134</sup>
</xref>. AUC may &#x02191; 6.5 fold <xref rid="apt15779-bib-0024" ref-type="ref">
<sup>24</sup>
</xref> Consider changing steroid agent or taking budesonide an hour before lopinavir/ritonavir<xref rid="apt15779-bib-0124" ref-type="ref">
<sup>124</sup>
</xref>
</p>
<p>&#x02191;<bold>Beclomethasone:</bold>
</p>
<p>Despite low bioavailability, increased absorption may occur, monitor for effect<xref rid="apt15779-bib-0069" ref-type="ref">
<sup>69</sup>
</xref>
</p>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<p>
<inline-graphic xlink:href="APT-9999-na-g002.jpg" xlink:title="image"/>
</p>
<p>&#x02191; Tacrolimus levels: perform levels, consider clinical need and cease</p>
<p>&#x02191; QT prolongation risk&#x02013; consider baseline and follow up ECG</p>
</td><td align="left" rowspan="1" colspan="1">
<p>
<inline-graphic xlink:href="APT-9999-na-g002.jpg" xlink:title="image"/>
</p>
<p>&#x02191; Ciclosporin levels: monitor levels, consider clinical need and dose reduction</p>
</td><td align="left" rowspan="1" colspan="1">
<p>
<inline-graphic xlink:href="APT-9999-na-g003.jpg" xlink:title="image"/>
</p>
<p>&#x02191;Tofacitinib</p>
<p>consider clinical need and cease. If necessary, use lowest dose tofacitinib possible</p>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>
<bold>Chloroquine</bold>
</p>
<p>
<bold>/ Hydroxychloroquine</bold>
</p>
<p>200&#x000a0;mg three times a day for 10 days</p>
<p>
<inline-graphic xlink:href="APT-9999-na-g006.jpg" xlink:title="image"/>
</p>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<p>
<inline-graphic xlink:href="APT-9999-na-g002.jpg" xlink:title="image"/>
</p>
<p>&#x02191;</p>
<p>myelosuppression risk. Recommend ceasing thiopurine in acute severe infection</p>
</td><td align="left" rowspan="1" colspan="1">
<p>
<inline-graphic xlink:href="APT-9999-na-g002.jpg" xlink:title="image"/>
</p>
<p>&#x02191;</p>
<p>myelosuppression risk. Recommend ceasing methotrexate in acute severe infection</p>
</td><td align="left" rowspan="1" colspan="1">
<p>
<inline-graphic xlink:href="APT-9999-na-g002.jpg" xlink:title="image"/>
</p>
<p>&#x02191; risk of QT&#x02010;interval prolongation. consider baseline and follow up ECG</p>
</td><td align="left" rowspan="1" colspan="1">
<p>
<inline-graphic xlink:href="APT-9999-na-g002.jpg" xlink:title="image"/>
</p>
<p>&#x02191; ciclosporin levels, perform levels if appropriate</p>
</td><td align="left" rowspan="1" colspan="1">
<p>
<inline-graphic xlink:href="APT-9999-na-g002.jpg" xlink:title="image"/>
</p>
<p>May &#x02191; tofacitinib, clinical significance unknown.</p>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Interferon beta</bold>
</td><td align="left" rowspan="1" colspan="1">
<p>
<inline-graphic xlink:href="APT-9999-na-g002.jpg" xlink:title="image"/>
</p>
<p>May &#x02191; corticosteroid levels, clinical significance unknown, monitor.</p>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<p>
<inline-graphic xlink:href="APT-9999-na-g002.jpg" xlink:title="image"/>
</p>
<p>May &#x02191; ciclosporin levels, clinical significance unknown, monitor levels</p>
</td><td align="left" rowspan="1" colspan="1">
<p>
<inline-graphic xlink:href="APT-9999-na-g002.jpg" xlink:title="image"/>
</p>
<p>May &#x02191; tofacitinib, clinical significance unknown, monitor. Consider lower dose where appropriate</p>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>
<bold>Ribavirin</bold>
</p>
<p>
<inline-graphic xlink:href="APT-9999-na-g004.jpg" xlink:title="image"/>
</p>
<p>Do not crush &#x02013;known teratogen.</p>
<p>Contact hospital pharmacy for solution compounded from capsules or (SAS) product availability</p>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<p>
<inline-graphic xlink:href="APT-9999-na-g003.jpg" xlink:title="image"/>
</p>
<p>&#x02191; risk of thiopurine induced myelosuppression</p>
<p>Cease thiopurine</p>
</td><td align="left" rowspan="1" colspan="1">
<p>
<inline-graphic xlink:href="APT-9999-na-g003.jpg" xlink:title="image"/>
</p>
<p>&#x02191; risk myelosuppression</p>
<p>Cease methotrexate</p>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>
<bold>Favipiravir</bold>
</p>
<p>
<inline-graphic xlink:href="APT-9999-na-g006.jpg" xlink:title="image"/>
</p>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>
<bold>Atazanavir</bold>
</p>
<p>
<inline-graphic xlink:href="APT-9999-na-g007.jpg" xlink:title="image"/>
</p>
<p>Requires pH &#x0003c;4. Avoid antacids 2 hours before and 1 hour after.</p>
<p>Food &#x02191; bioavailability</p>
<p>Absorbed in jejunum: NG ok; NJ may &#x02193; effect</p>
</td><td align="left" rowspan="1" colspan="1">
<p>
<inline-graphic xlink:href="APT-9999-na-g002.jpg" xlink:title="image"/>
</p>
<p>&#x02191; <bold>Methylprednisolone:</bold> Consider 50% dose reduction <xref rid="apt15779-bib-0124" ref-type="ref">
<sup>124</sup>
</xref>.</p>
<p>&#x02191; <bold>Prednisolone:</bold>
</p>
<p>&#x02193; plasma cortisol (level if appropriate)</p>
<p>&#x02191; <bold>Budesonide:</bold>
</p>
<p>10&#x02010;20% absorbed<xref rid="apt15779-bib-0134" ref-type="ref">
<sup>134</sup>
</xref>. AUC may &#x02191; 6.5 fold <sup>24</sup> Consider changing steroid agent or taking budesonide an hour before lopinavir/ritonavir<xref rid="apt15779-bib-0124" ref-type="ref">
<sup>124</sup>
</xref>
</p>
<p>&#x02191;<bold>Beclomethasone:</bold>
</p>
<p>Despite low bioavailability, increased absorption may occur, monitor for effect<xref rid="apt15779-bib-0069" ref-type="ref">
<sup>69</sup>
</xref>
</p>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<p>
<inline-graphic xlink:href="APT-9999-na-g003.jpg" xlink:title="image"/>
</p>
<p>&#x02191; ciclosporin and &#x02191; atazanavir.</p>
<p>Do not co&#x02010;administer.</p>
</td><td align="left" rowspan="1" colspan="1">
<p>
<inline-graphic xlink:href="APT-9999-na-g003.jpg" xlink:title="image"/>
</p>
<p>&#x02191; tofacitinib, recommend ceasing tofacitinib</p>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>
<bold>Nitazoxanide (prodrug)</bold>
</p>
<p>
<bold>(active metabolite: tizoxanide)</bold>
</p>
<p>
<bold>May be dispersible or crushed&#x02013; check brand</bold>
</p>
<p>Take with food &#x02010; increases bioavailability by 50%.</p>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Tocilizumab (IL&#x02010;6 monoclonal antibody)</bold>
</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image"/>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="apt15779-ntgp-0030"><fn id="apt15779-note-0030"><p>
<inline-graphic xlink:href="APT-9999-na-g006.jpg" xlink:title="image"/> Can be crushed; <inline-graphic xlink:href="APT-9999-na-g007.jpg" xlink:title="image"/> Can open capsule; <inline-graphic xlink:href="APT-9999-na-g004.jpg" xlink:title="image"/> Do not crush; <inline-graphic xlink:href="APT-9999-na-g005.jpg" xlink:title="image"/> Liquid product available; No clinically significant interaction expected; <inline-graphic xlink:href="APT-9999-na-g002.jpg" xlink:title="image"/> Interaction, monitor and dose adjust as required; <inline-graphic xlink:href="APT-9999-na-g003.jpg" xlink:title="image"/> Do not administer due to interaction and clinical setting</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions></table-wrap><sec id="apt15779-sec-0026"><label>6.1</label><title>Remdesivir (GS&#x02010;5734)</title><p>Remdesivir is a prodrug of the adenosine nucleotide analogue GS&#x02010;441524 that incorporates into nascent viral RNA chains, inhibiting virus infection in a human cell line (human liver cancer Huh 7 cells).<xref rid="apt15779-bib-0102" ref-type="ref">
<sup>102</sup>
</xref>, <xref rid="apt15779-bib-0103" ref-type="ref">
<sup>103</sup>
</xref> It appears to be effective against RNA viruses SARS, MERS and Ebola.<xref rid="apt15779-bib-0103" ref-type="ref">
<sup>103</sup>
</xref> In MERS&#x02010;CoV mouse models, it has been found to reduce the virus titre and improve lung tissue damage.<xref rid="apt15779-bib-0104" ref-type="ref">
<sup>104</sup>
</xref> There are currently multiple phase III studies of remdesivir in COVID&#x02010;19 patients.</p></sec><sec id="apt15779-sec-0027"><label>6.2</label><title>Lopinavir/ritonavir (Kaltera; 400mg/100mg)</title><p>Lopinavir/ritonavir combines two protease inhibitors, the latter used to pharmacokinetically &#x02018;boost&#x02019; lopinavir concentrations and prolong the effect through CYP3A4 inhibition.<xref rid="apt15779-bib-0104" ref-type="ref">
<sup>104</sup>
</xref> Licensed as an HIV treatment, in vitro and animal model use in SARS and MERS&#x02010;CoV resulted in a lower risk of ARDS, lower viral load in lung and extrapulmonary tissue and reduced mortality.<xref rid="apt15779-bib-0104" ref-type="ref">
<sup>104</sup>
</xref>, <xref rid="apt15779-bib-0105" ref-type="ref">
<sup>105</sup>
</xref>, <xref rid="apt15779-bib-0106" ref-type="ref">
<sup>106</sup>
</xref> Results from a recent human trial in China did not demonstrate a statistically significant improvement in time to discharge or clinical improvement. However, treatment was commenced late in the diseases course and only in patients who had developed very severe disease.<xref rid="apt15779-bib-0107" ref-type="ref">
<sup>107</sup>
</xref> Further trials are needed to determine the utility of this medication regime. Importantly lopinavir/ritonavir inhibits the metabolism of corticosteroids, tacrolimus, ciclosporin and tofacitinib which may lead to toxicity (Table&#x000a0;<xref rid="apt15779-tbl-0004" ref-type="table">4</xref>).</p></sec><sec id="apt15779-sec-0028"><label>6.3</label><title>Chloroquine or hydroxychloroquine</title><p>Chloroquine is a widely used anti&#x02010;malarial and autoimmune disease drug. It has a broad spectrum anti&#x02010;viral action that is exerted on SARS&#x02010;CoV by inhibiting the pre&#x02010;entry point of the viral cycle by interfering with viral binding to cell surface, increasing endosomal pH required for virus/cell fusion and interfering with the glycosylation of cell surface receptors (ACE 2).<xref rid="apt15779-bib-0108" ref-type="ref">
<sup>108</sup>
</xref> It also has immunomodulator properties against many cytokines (IL&#x02010;1b, IL&#x02010;1, IL&#x02010;6, IL&#x02010;12, TNF&#x02010;a, INF&#x02010;a, IFNb, IFNy,) which may enhance its anti&#x02010;viral effect and reduce COVID&#x02010;19 complications synergistically.<xref rid="apt15779-bib-0108" ref-type="ref">
<sup>108</sup>
</xref>
</p><p>Compared to controls, chloroquine had a superior effect in 100 patients in China infected with COVID&#x02010;19 in terms of a reduction in exacerbation of pneumonia, duration of symptoms and delay in viral clearance.<xref rid="apt15779-bib-0109" ref-type="ref">
<sup>109</sup>
</xref> Chloroquine is not accessible in Australia and it has been suggested that hydroxychloroquine could be an effective alternative given that it is an identical molecule to chloroquine apart from the addition of a hydroxyl group. <xref rid="apt15779-bib-0108" ref-type="ref">
<sup>108</sup>
</xref>, <xref rid="apt15779-bib-0110" ref-type="ref">
<sup>110</sup>
</xref> In a French study, 20 COVID&#x02010;19 positive patients (&#x0003e;12&#x000a0;years of age) received hydroxychloroquine 200&#x000a0;mg three times a day for 10&#x000a0;days after a mean of 4&#x000a0;&#x000b1;&#x000a0;2.6&#x000a0;days from the onset of symptoms. At day 6, virological clearance was 57% in those receiving hydroxychloroquine compared with 12.5% in the control group (<italic>P</italic>&#x000a0;=&#x000a0;.001). In those who also received azithromycin, virological clearance was 100%.<xref rid="apt15779-bib-0111" ref-type="ref">
<sup>111</sup>
</xref> A limitation of this study was the exclusion of patients who discontinued treatment, including three patients who were transferred to ICU. Furthermore, the combination of azithromycin and hydroxychloroquine should be considered with caution given additive potential of QT prolongation. More evidence is required before this treatment can be recommended.</p></sec><sec id="apt15779-sec-0029"><label>6.4</label><title>Favipiravir (T&#x02010;705)</title><p>Favipiravir, a guanine analogue, effectively inhibits the RNA&#x02010;dependent polymerase of RNA viruses. This anti&#x02010;viral effect has efficacy on influenza (approved use), Ebola, yellow fever, chikungunya, norovirus and enterovirus. Activity against COVID&#x02010;19 has been reported.<xref rid="apt15779-bib-0112" ref-type="ref">
<sup>112</sup>
</xref> It is currently being tested in Japan and has no significant drug interactions. In a recent study it has been reported to improve clinical recovery rates at day 7 when compared to arbidol, a flu medication (71% vs. 56%) but there was no difference in auxiliary oxygen or non&#x02010;invasive ventilation requirements.<xref rid="apt15779-bib-0113" ref-type="ref">
<sup>113</sup>
</xref>
</p></sec><sec id="apt15779-sec-0030"><label>6.5</label><title>Alternative therapies</title><p>Finally, of note as of 12 March 2020, 379 trials for COVID&#x02010;19 had been listed on the Chinese Clinical trials Registry; by 15 March 2020 this increased to 420.<xref rid="apt15779-bib-0114" ref-type="ref">
<sup>114</sup>
</xref> (Table&#x000a0;<xref rid="apt15779-sup-0001" ref-type="supplementary-material">S1</xref>). Of these trials, 122 (29%) involved the examination of Chinese medicines for the treatment of COVID&#x02010;19. As clinicians we need to be aware of the information available to patients seeking &#x02018;natural&#x02019; alternative therapies and in the absence of clinical evidence, care should be taken when making such suggestions to alleviate panic and inappropriate prescribing.</p></sec></sec><sec sec-type="summary" id="apt15779-sec-0031"><label>7</label><title>SUMMARY</title><p>IBD patients present a unique challenge in the setting of the current COVID&#x02010;19 pandemic. Of concern is that, at least theoretically, many medications used to treat IBD may result in a degree of immunosuppression and this may lead to an increased risk of infection with SARS&#x02010;CoV&#x02010;2 and complications arising from COVID&#x02010;19. Despite this, global registries and reports are reassuring and there does not appear to be a signal that IBD patients are at greater risk or severe COVID&#x02010;19 compared to the general population. These guidelines summarise the treatment approach to IBD patients in the current climate and emphasises the importance of avoiding corticosteroids and maintaining remission by encouraging compliance with patients&#x02019; usual maintenance medications. If an IBD patient does develop COVID&#x02010;19, immunosuppressive medications should be withheld where possible until infection resolution and if a medication trial is being considered and patients remain on IBD medications, interactions with current IBD medications should be evaluated.</p></sec><sec id="apt15779-sec-0033"><title>AUTHORSHIP</title><p>
<italic>Guarantor of the article</italic>: Britt Christensen.</p><p>
<italic>Author contributions</italic>: Aysha H. Al&#x02010;Ani, Ralley E. Prentice and Clarissa&#x000a0;A. Rentsch reviewed the literature, provided the analysis and drafted the manuscript. Doug Johnson helped to develop the concept of paper, provided ID advice on COVID and its risk and reviewed the manuscript. Zaid Ardalan, Neel Heerasing, Mayur Garg and Finlay A. Macrae contributed to the writing and revision of the manuscript. Sian Campbell and Joe Sasadeusz&#x000a0;were involved in the literature review, drafting of COVID medical therapies section and revision of manuscript. Siew C. Ng and David T. Rubin helped to develop the concept and revision of manuscript. Britt Christensen designed the study, led the analysis and interpretation of data, and&#x000a0;coordinated the writing and revision of manuscript.</p><p>All the authors approved the final version of the manuscript.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="apt15779-sup-0001"><caption><p>Table S1</p></caption><media xlink:href="APT-9999-na-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="apt15779-sec-0032"><title>ACKNOWLEDGEMENTS</title><p>
<italic>Declaration of personal interests</italic>: Aysha H. Al&#x02010;Ani, Ralley E. Prentice, Zaid Ardalan, Neel Heerasing, Sian Cambell: None. Clarissa A. Rentsch and Doug Johnson have served as speakers for Pfizer. Mayur Garg has served on the advisory board of Pfizer and Pharmacosmos and has received speaker fees, research or travel grants from Abbvie, Janssen, Pfizer, Pharmacosmos, Shire, Takeda and Vifor. Joe Sasadeusz has received research funding from Gilead. Finlay A. Macrae has served as an&#x000a0;advisory board member for Rhythm BioSciences, Endogene, Glutagen, and has received research funding from Rhythm Biosciences for clinical trial support in biomarkers of colorectal cancer research. Finlay A. Macrae&#x000a0;owns stocks and shares in a superannuation portfolio with to his knowledge no relationship with the current paper. Siew C. Ng has received search grants from Ferring and Abbvie and speakers honorarium from Janssen, Abbvie, Tillotts, Takeda, Olympus and Ferring. David T. Rubin reports grants and personal fees from Abbvie, personal fees from Abgenomics, personal fees from Allergan Inc, personal fees from Boehringer Ingelheim Ltd, personal fees from Bristol&#x02010;Myers Squibb, personal fees from Celgene Corp/Syneos, personal fees from Check&#x02010;cap, personal fees from Dizal Pharmaceuticals, personal fees from GalenPharma/Atlantica, grants and personal fees from Genentech/Roche, personal fees from Gilead Sciences, personal fees from Ichnos Sciences, personal fees from GlaxoSmithKline Group, grants and personal fees from Janssen Pharmaceuticals, personal fees from Lilly, personal fees from Narrow River Mgmt, personal fees from Pfizer, grants and personal fees from Prometheus Laboratories, personal fees from Reistone, grants and personal fees from Shire, grants and personal fees from Takeda, personal fees from Techlab, Inc, outside the submitted work. Britt Christensen has received speaking fees from Abbvie, Jannsen, Pfizer, Takeda and Ferring, research grants from Janssen and Ferring Pharmaceuticals and served on the advisory board of Gilead and Novartis.</p></ack><ref-list content-type="cited-references" id="apt15779-bibl-0001"><title>References</title><ref id="apt15779-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="apt15779-cit-0001">
<string-name>
<surname>Wang</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus&#x02010;infected pneumonia in Wuhan, China</article-title>. <source xml:lang="en">JAMA</source>. <year>2020</year>.</mixed-citation></ref><ref id="apt15779-bib-0002"><label>2</label><mixed-citation publication-type="miscellaneous" id="apt15779-cit-0002">
<collab collab-type="authors">World Health Organisation</collab>
. <article-title>WHO Director&#x02010;General's opening remarks at the media briefing on COVID&#x02010;19&#x02014;11 March 2020</article-title>. March 16, 2020. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19%2013-11-march-2020">https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19%2013-11-march-2020</ext-link>.</mixed-citation></ref><ref id="apt15779-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="apt15779-cit-0003">
<string-name>
<surname>Chan</surname>
<given-names>J&#x02010;W</given-names>
</string-name>, <string-name>
<surname>To</surname>
<given-names>K&#x02010;W</given-names>
</string-name>, <string-name>
<surname>Tse</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Interspecies transmission and emergence of novel viruses: lessons from bats and birds</article-title>. <source xml:lang="en">Trends Microbiol</source>. <year>2013</year>;<volume>21</volume>:<fpage>544</fpage>&#x02013;<lpage>555</lpage>.<pub-id pub-id-type="pmid">23770275</pub-id></mixed-citation></ref><ref id="apt15779-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="apt15779-cit-0004">
<string-name>
<surname>Ghosh</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Premchand</surname>
<given-names>P</given-names>
</string-name>. <article-title>A UK cost of care model for inflammatory bowel disease</article-title>. <source xml:lang="en">Frontline Gastroenterol</source>. <year>2015</year>;<volume>6</volume>:<fpage>169</fpage>&#x02013;<lpage>174</lpage>.<pub-id pub-id-type="pmid">28839807</pub-id></mixed-citation></ref><ref id="apt15779-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="apt15779-cit-0005">
<string-name>
<surname>Jeong</surname>
<given-names>DY</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Son</surname>
<given-names>MJ</given-names>
</string-name>, et al. <article-title>Induction and maintenance treatment of inflammatory bowel disease: a comprehensive review</article-title>. <source xml:lang="en">Autoimmun Rev</source>. <year>2019</year>;<volume>18</volume>:<fpage>439</fpage>&#x02013;<lpage>454</lpage>.<pub-id pub-id-type="pmid">30844556</pub-id></mixed-citation></ref><ref id="apt15779-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="apt15779-cit-0006">
<string-name>
<surname>Rahier</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Magro</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Abreu</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Second European evidence&#x02010;based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease</article-title>. <source xml:lang="en">J Crohns Colitis</source>. <year>2014</year>;<volume>8</volume>:<fpage>443</fpage>&#x02013;<lpage>468</lpage>.<pub-id pub-id-type="pmid">24613021</pub-id></mixed-citation></ref><ref id="apt15779-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="apt15779-cit-0007">
<string-name>
<surname>Weiss</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Navas&#x02010;Martin</surname>
<given-names>S</given-names>
</string-name>. <article-title>Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus</article-title>. <source xml:lang="en">Microbiol Mol Biol Rev</source>. <year>2005</year>;<volume>69</volume>:<fpage>635</fpage>&#x02013;<lpage>664</lpage>.<pub-id pub-id-type="pmid">16339739</pub-id></mixed-citation></ref><ref id="apt15779-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="apt15779-cit-0008">
<string-name>
<surname>Lai</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Cavanagh</surname>
<given-names>D</given-names>
</string-name>. <article-title>The molecular biology of coronaviruses</article-title>. <source xml:lang="en">Adv Virus Res</source>. <year>1997</year>;<volume>48</volume>:<fpage>1</fpage>&#x02013;<lpage>100</lpage>.<pub-id pub-id-type="pmid">9233431</pub-id></mixed-citation></ref><ref id="apt15779-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="apt15779-cit-0009">
<string-name>
<surname>Su</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>W</given-names>
</string-name>, et al. <article-title>Epidemiology, genetic recombination, and pathogenesis of coronaviruses</article-title>. <source xml:lang="en">Trends Microbiol</source>. <year>2016</year>;<volume>24</volume>(<issue>6</issue>):<fpage>490</fpage>&#x02013;<lpage>502</lpage>.<pub-id pub-id-type="pmid">27012512</pub-id></mixed-citation></ref><ref id="apt15779-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="apt15779-cit-0010">
<string-name>
<surname>Monto</surname>
<given-names>AS</given-names>
</string-name>. <article-title>Medical reviews. Coronaviruses</article-title>. <source xml:lang="en">Yale J Biol Med</source>. <year>1974</year>;<volume>47</volume>:<fpage>234</fpage>&#x02013;<lpage>251</lpage>.<pub-id pub-id-type="pmid">4617423</pub-id></mixed-citation></ref><ref id="apt15779-bib-0011"><label>11</label><mixed-citation publication-type="miscellaneous" id="apt15779-cit-0011">
<collab collab-type="authors">Centres for Disease Control and Prevention</collab>
. <article-title>Middle East Respiratory Syndrome (MERS)</article-title>. 2016 Updated August 2, 2019. <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/sars/index.html">https://www.cdc.gov/sars/index.html</ext-link>
</mixed-citation></ref><ref id="apt15779-bib-0012"><label>12</label><mixed-citation publication-type="miscellaneous" id="apt15779-cit-0012">
<collab collab-type="authors">Centres for Disease Control and Prevention</collab>
. <article-title>Severe Acute Respiratory Syndrome (SARS)</article-title>. <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/sars/index.html">https://www.cdc.gov/sars/index.html</ext-link>. Accessed 15 March, 2020.</mixed-citation></ref><ref id="apt15779-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="apt15779-cit-0013">
<string-name>
<surname>Lu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Stratton</surname>
<given-names>CW</given-names>
</string-name>, <string-name>
<surname>Tang</surname>
<given-names>YW</given-names>
</string-name>. <article-title>Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle</article-title>. <source xml:lang="en">J Med Virol</source>. <year>2020</year>;<volume>92</volume>:<fpage>401</fpage>&#x02013;<lpage>402</lpage>.<pub-id pub-id-type="pmid">31950516</pub-id></mixed-citation></ref><ref id="apt15779-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="apt15779-cit-0014">
<string-name>
<surname>Chan</surname>
<given-names>J&#x02010;W</given-names>
</string-name>, <string-name>
<surname>Kok</surname>
<given-names>K&#x02010;H</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>Z</given-names>
</string-name>, et al. <article-title>Genomic characterization of the 2019 novel human&#x02010;pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan</article-title>. <source xml:lang="en">Emerg Microbes Infect</source>. <year>2020</year>;<volume>9</volume>:<fpage>221</fpage>&#x02013;<lpage>236</lpage>.<pub-id pub-id-type="pmid">31987001</pub-id></mixed-citation></ref><ref id="apt15779-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="apt15779-cit-0015">
<string-name>
<surname>Zhang</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</string-name>. <article-title>Probable pangolin origin of SARS&#x02010;CoV&#x02010;2 associated with the COVID&#x02010;19 outbreak</article-title>. <source xml:lang="en">Curr Biol</source>. <year>2020</year>.</mixed-citation></ref><ref id="apt15779-bib-0016"><label>16</label><mixed-citation publication-type="miscellaneous" id="apt15779-cit-0016">
<collab collab-type="authors">World Health Organisation</collab>
. <article-title>Report of the WHO&#x02010;China Joint Mission on Coronavirus Disease 2019 (COVID&#x02010;19)</article-title>. March 16, 2020. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf">https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf</ext-link>
</mixed-citation></ref><ref id="apt15779-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="apt15779-cit-0017">
<string-name>
<surname>Guan</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Ni</surname>
<given-names>ZY</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2020</year>.</mixed-citation></ref><ref id="apt15779-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="apt15779-cit-0018">
<string-name>
<surname>Gu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>J</given-names>
</string-name>. <article-title>COVID&#x02010;19: Gastrointestinal manifestations and potential fecal&#x02010;oral transmission</article-title>. <source xml:lang="en">Gastroenterology</source>. <year>2020</year>.</mixed-citation></ref><ref id="apt15779-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="apt15779-cit-0019">
<string-name>
<surname>Tian</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Rong</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Nian</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>He</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Review article: gastrointestinal features in COVID&#x02010;19 and the possibility of faecal transmission</article-title>. <source xml:lang="en">Aliment Pharmacol Ther</source>. <year>2020</year>;<volume>51</volume>:<fpage>843</fpage>&#x02013;<lpage>851</lpage>.<pub-id pub-id-type="pmid">32222988</pub-id></mixed-citation></ref><ref id="apt15779-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="apt15779-cit-0020">
<string-name>
<surname>Zhang</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Diao</surname>
<given-names>MengYuan</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>W</given-names>
</string-name>, et al. <article-title>Estimation of the reproductive number of novel coronavirus (COVID&#x02010;19) and the probable outbreak size on the Diamond Princess cruise ship: a data&#x02010;driven analysis</article-title>. <source xml:lang="en">Int J Infect Dis</source>. <year>2020</year>;<volume>93</volume>:<fpage>201</fpage>&#x02013;<lpage>204</lpage>.<pub-id pub-id-type="pmid">32097725</pub-id></mixed-citation></ref><ref id="apt15779-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="apt15779-cit-0021">
<string-name>
<surname>Hoffmann</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kleine&#x02010;Weber</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Schroeder</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>SARS&#x02010;CoV&#x02010;2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title>. <source xml:lang="en">Cell</source>. <year>2020</year>.</mixed-citation></ref><ref id="apt15779-bib-0022"><label>22</label><mixed-citation publication-type="miscellaneous" id="apt15779-cit-0022">
<string-name>
<surname>Zhang</surname>
<given-names>HKZ</given-names>
</string-name>, <string-name>
<surname>Gong</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Cui</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Xiao</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Meng</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>H</given-names>
</string-name>.<article-title>The digestive system is a potential route of 2019&#x02010;nCov infection: a bioinformatics analysis based on single&#x02010;cell transcriptomes</article-title>. <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2020.01.30.927806v1">https://www.biorxiv.org/content/10.1101/2020.01.30.927806v1</ext-link>. March 16, 2020.</mixed-citation></ref><ref id="apt15779-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="apt15779-cit-0023">
<string-name>
<surname>Garg</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Royce</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Tikellis</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Imbalance of the renin&#x02010;angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?</article-title>
<source xml:lang="en">Gut</source>. <year>2019</year>.</mixed-citation></ref><ref id="apt15779-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="apt15779-cit-0024">
<string-name>
<surname>Zhou</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Du</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Clinical course and risk factors for mortality of adult inpatients with COVID&#x02010;19 in Wuhan, China: a retrospective cohort study</article-title>. <source xml:lang="en">Lancet</source>. <year>2020</year>;<volume>395</volume>:<fpage>1054</fpage>&#x02013;<lpage>1062</lpage>.<pub-id pub-id-type="pmid">32171076</pub-id></mixed-citation></ref><ref id="apt15779-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="apt15779-cit-0025">
<string-name>
<surname>Prescott</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Falzarano</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>de Wit</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Pathogenicity and viral shedding of MERS&#x02010;CoV in immunocompromised rhesus macaques</article-title>. <source xml:lang="en">Front Immunol</source>. <year>2018</year>;<volume>9</volume>:<fpage>205</fpage>.<pub-id pub-id-type="pmid">29483914</pub-id></mixed-citation></ref><ref id="apt15779-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="apt15779-cit-0026">
<string-name>
<surname>Eichenberger</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Soave</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Zappetti</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Incidence, significance, and persistence of human coronavirus infection in hematopoietic stem cell transplant recipients</article-title>. <source xml:lang="en">Bone Marrow Transplant</source>. <year>2019</year>;<volume>54</volume>(<issue>7</issue>):<fpage>1058</fpage>&#x02013;<lpage>1066</lpage>.<pub-id pub-id-type="pmid">30385869</pub-id></mixed-citation></ref><ref id="apt15779-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="apt15779-cit-0027">
<string-name>
<surname>W&#x000f6;lfel</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Corman</surname>
<given-names>VM</given-names>
</string-name>, <string-name>
<surname>Guggemos</surname>
<given-names>W</given-names>
</string-name>, et al. <article-title>Virological assessment of hospitalized patients with COVID&#x02010;2019</article-title>. <source xml:lang="en">Nature</source>. <year>2020</year>.</mixed-citation></ref><ref id="apt15779-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="apt15779-cit-0028">
<string-name>
<surname>Rothe</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Schunk</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sothmann</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Transmission of 2019&#x02010;nCoV infection from an asymptomatic contact in Germany</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2020</year>;<volume>382</volume>:<fpage>970</fpage>&#x02013;<lpage>971</lpage>.<pub-id pub-id-type="pmid">32003551</pub-id></mixed-citation></ref><ref id="apt15779-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="apt15779-cit-0029">
<string-name>
<surname>Xiao</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Tang</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>Evidence for gastrointestinal infection of SARS&#x02010;CoV&#x02010;2</article-title>. <source xml:lang="en">Gastroenterology</source>. <year>2020</year>;<volume>158</volume>:<fpage>1831</fpage>&#x02013;<lpage>1833</lpage>.<pub-id pub-id-type="pmid">32142773</pub-id></mixed-citation></ref><ref id="apt15779-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="apt15779-cit-0030">
<string-name>
<surname>Pan</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Mu</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Clinical characteristics of COVID&#x02010;19 patients with digestive symptoms in Hubei, China</article-title>. <source xml:lang="en">Am J Gastroenterol</source>. <year>2020</year>;<volume>115</volume>:<fpage>766</fpage>&#x02013;<lpage>773</lpage> (In Press).<pub-id pub-id-type="pmid">32287140</pub-id></mixed-citation></ref><ref id="apt15779-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="apt15779-cit-0031">
<string-name>
<surname>Carvalho</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Alqusairi</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Adams</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>SARS&#x02010;CoV&#x02010;2 gastrointestinal infection causing hemorrhagic colitis: implications for detection and transmission of COVID&#x02010;19 disease</article-title>. <source xml:lang="en">Am J Gastroenterol</source>. <year>2020</year>;In Press.</mixed-citation></ref><ref id="apt15779-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="apt15779-cit-0032">
<string-name>
<surname>van Doremalen</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Bushmaker</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Morris</surname>
<given-names>DH</given-names>
</string-name>, et al. <article-title>Aerosol and surface stability of SARS&#x02010;CoV&#x02010;2 as compared with SARS&#x02010;CoV&#x02010;1</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2020</year>.</mixed-citation></ref><ref id="apt15779-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="apt15779-cit-0033">
<collab collab-type="authors">The Lancet</collab>
. <article-title>COVID&#x02010;19: protecting health&#x02010;care workers</article-title>. <source xml:lang="en">Lancet</source>. <year>2020</year>;<volume>395</volume>:<fpage>922</fpage>.</mixed-citation></ref><ref id="apt15779-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="apt15779-cit-0034">
<string-name>
<surname>Lauer</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Grantz</surname>
<given-names>KH</given-names>
</string-name>, <string-name>
<surname>Bi</surname>
<given-names>Q</given-names>
</string-name>, et al. <article-title>The incubation period of coronavirus disease 2019 (COVID&#x02010;19) from publicly reported confirmed cases: estimation and application</article-title>. <source xml:lang="en">Ann Intern Med</source>. <year>2020</year>;<volume>172</volume>:<fpage>577</fpage>.<pub-id pub-id-type="pmid">32150748</pub-id></mixed-citation></ref><ref id="apt15779-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="apt15779-cit-0035">
<string-name>
<surname>Li</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Guan</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Early transmission dynamics in Wuhan, China, of novel coronavirus&#x02010;infected pneumonia</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2020</year>.</mixed-citation></ref><ref id="apt15779-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="apt15779-cit-0036">
<string-name>
<surname>Wu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>McGoogan</surname>
<given-names>JM</given-names>
</string-name>. <article-title>Characteristics of and important lessons from the coronavirus disease 2019 (COVID&#x02010;19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention</article-title>. <source xml:lang="en">JAMA</source>. <year>2020</year>.</mixed-citation></ref><ref id="apt15779-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="apt15779-cit-0037">
<string-name>
<surname>Brake</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Barnsley</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>W</given-names>
</string-name>, et al. <article-title>Smoking upregulates angiotensin&#x02010;converting enzyme&#x02010;2 receptor: a potential adhesion site for novel coronavirus SARS&#x02010;CoV&#x02010;2 (Covid&#x02010;19)</article-title>. <source xml:lang="en">J Clin Med</source>. <year>2020</year>;<volume>9</volume>:<fpage>841</fpage>.</mixed-citation></ref><ref id="apt15779-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="apt15779-cit-0038">
<string-name>
<surname>Chan</surname>
<given-names>J&#x02010;W</given-names>
</string-name>, <string-name>
<surname>Yuan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kok</surname>
<given-names>K&#x02010;H</given-names>
</string-name>, et al. <article-title>A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person&#x02010;to&#x02010;person transmission: a study of a family cluster</article-title>. <source xml:lang="en">Lancet</source>. <year>2020</year>;<volume>395</volume>:<fpage>514</fpage>&#x02013;<lpage>523</lpage>.<pub-id pub-id-type="pmid">31986261</pub-id></mixed-citation></ref><ref id="apt15779-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="apt15779-cit-0039">
<string-name>
<surname>Dong</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Mo</surname>
<given-names>XI</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Epidemiology of COVID&#x02010;19 among children in China</article-title>. <source xml:lang="en">Pediatrics</source>. <year>2020</year>.</mixed-citation></ref><ref id="apt15779-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="apt15779-cit-0040">
<string-name>
<surname>Hakki</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rattray</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Press</surname>
<given-names>RD</given-names>
</string-name>. <article-title>The clinical impact of coronavirus infection in patients with hematologic malignancies and hematopoietic stem cell transplant recipients</article-title>. <source xml:lang="en">J Clin Virol</source>. <year>2015</year>;<volume>68</volume>:<fpage>1</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">26071326</pub-id></mixed-citation></ref><ref id="apt15779-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="apt15779-cit-0041">
<string-name>
<surname>Toruner</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Loftus</surname>
<given-names>EV</given-names>
</string-name>, <string-name>
<surname>Harmsen</surname>
<given-names>WS</given-names>
</string-name>, et al. <article-title>Risk factors for opportunistic infections in patients with inflammatory bowel disease</article-title>. <source xml:lang="en">Gastroenterology</source>. <year>2008</year>;<volume>134</volume>:<fpage>929</fpage>&#x02013;<lpage>936</lpage>.<pub-id pub-id-type="pmid">18294633</pub-id></mixed-citation></ref><ref id="apt15779-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="apt15779-cit-0042">
<string-name>
<surname>Tosca</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Garcia</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Pascual</surname>
<given-names>I</given-names>
</string-name>, et al. <article-title>Clinical assessment of risk factors for infection in inflammatory bowel disease patients</article-title>. <source xml:lang="en">Int J Colorectal Dis</source>. <year>2020</year>;<volume>35</volume>:<fpage>491</fpage>&#x02013;<lpage>500</lpage>.<pub-id pub-id-type="pmid">31915983</pub-id></mixed-citation></ref><ref id="apt15779-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="apt15779-cit-0043">
<string-name>
<surname>Aberra</surname>
<given-names>FN</given-names>
</string-name>, <string-name>
<surname>Lichtenstein</surname>
<given-names>GR</given-names>
</string-name>. <article-title>Methods to avoid infections in patients with inflammatory bowel disease</article-title>. <source xml:lang="en">Inflamm Bowel Dis</source>. <year>2005</year>;<volume>11</volume>:<fpage>685</fpage>&#x02013;<lpage>695</lpage>.<pub-id pub-id-type="pmid">15973124</pub-id></mixed-citation></ref><ref id="apt15779-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="apt15779-cit-0044">
<string-name>
<surname>Wisniewski</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kirchgesner</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Seksik</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines</article-title>. <source xml:lang="en">United European Gastroenterology Journal</source>. <year>2019</year>;<fpage>2050640619889763</fpage>.</mixed-citation></ref><ref id="apt15779-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="apt15779-cit-0045">
<string-name>
<surname>Grant</surname>
<given-names>WB</given-names>
</string-name>, <string-name>
<surname>Lahore</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>McDonnell</surname>
<given-names>SL</given-names>
</string-name>, et al. <article-title>Evidence that vitamin D supplementation could reduce risk of influenza and COVID&#x02010;19 infections and deaths</article-title>. <source xml:lang="en">Nutrients</source>. <year>2020</year>;<volume>12</volume>:<fpage>988</fpage>.</mixed-citation></ref><ref id="apt15779-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="apt15779-cit-0046">
<string-name>
<surname>Panarese</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Shahini</surname>
<given-names>E</given-names>
</string-name>. <article-title>Letter: Covid&#x02010;19, and vitamin D</article-title>. <source xml:lang="en">Aliment Pharmacol Ther</source>. <year>2020</year>;<volume>51</volume>:<fpage>993</fpage>&#x02013;<lpage>995</lpage>.<pub-id pub-id-type="pmid">32281109</pub-id></mixed-citation></ref><ref id="apt15779-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="apt15779-cit-0047">
<string-name>
<surname>Tian</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Rong</surname>
<given-names>L</given-names>
</string-name>. <article-title>Letter: Covid&#x02010;19 and vitamin D&#x02010;authors' reply</article-title>. <source xml:lang="en">Aliment Pharmacol Ther</source>. <year>2020</year>;<volume>51</volume>:<fpage>995</fpage>&#x02013;<lpage>996</lpage>.<pub-id pub-id-type="pmid">32286694</pub-id></mixed-citation></ref><ref id="apt15779-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="apt15779-cit-0048">
<string-name>
<surname>Ning</surname>
<given-names>LongGui</given-names>
</string-name>, <string-name>
<surname>Shan</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>Z</given-names>
</string-name>, et al. <article-title>Quantitative proteomic analysis reveals the deregulation of nicotinamide adenine dinucleotide metabolism and CD38 in inflammatory bowel disease</article-title>. <source xml:lang="en">Biomed Res Int</source>. <year>2019</year>;<volume>2019</volume>:<fpage>3950628</fpage>.<pub-id pub-id-type="pmid">31179321</pub-id></mixed-citation></ref><ref id="apt15779-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="apt15779-cit-0049">
<string-name>
<surname>An</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Menguao</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Megyao</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Protection of 318 inflammatory bowel disease patients from the outbreak and rapid spread of COVID&#x02010;19 infection in Wuhan, China</article-title>. <source xml:lang="en">Lancet</source>. <year>2020</year> (In Press).</mixed-citation></ref><ref id="apt15779-bib-0050"><label>50</label><mixed-citation publication-type="miscellaneous" id="apt15779-cit-0050">
<string-name>
<surname>Brenner</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Ungaro</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Colombel</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Kappelman</surname>
<given-names>MD</given-names>
</string-name>.<article-title>Secure&#x02010;IBD Database Public Data Update 2020</article-title>. <ext-link ext-link-type="uri" xlink:href="https://covidibd.org/">https://covidibd.org/</ext-link>
</mixed-citation></ref><ref id="apt15779-bib-0051"><label>51</label><mixed-citation publication-type="miscellaneous" id="apt15779-cit-0051">
<string-name>
<surname>Han</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Duan</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>S</given-names>
</string-name>, et al. Clinical characteristics of COVID&#x02010;19 patients with digestive symptoms in Hubei, China. Am J Gastroenterol. <year>2020</year>; EPub Ahead of Print.</mixed-citation></ref><ref id="apt15779-bib-0052"><label>52</label><mixed-citation publication-type="miscellaneous" id="apt15779-cit-0052">
<collab collab-type="authors">Centers for Disease Control and Prevention</collab>
. <article-title>Testing for COVID&#x02010;19</article-title>. <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html?CDC_AA_refVal=https%253A%252F%252Fwww.cdc.gov%252Fcoronavirus%252F2019-ncov%252Fclinical-criteria.html">https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html?CDC_AA_refVal=https%253A%252F%252Fwww.cdc.gov%252Fcoronavirus%252F2019-ncov%252Fclinical-criteria.html</ext-link>. Accessed March 18, 2020.</mixed-citation></ref><ref id="apt15779-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="apt15779-cit-0053">
<string-name>
<surname>Ransford</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Langman</surname>
<given-names>M</given-names>
</string-name>. <article-title>Sulphasalazine and mesalazine: serious adverse reactions re&#x02010;evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines</article-title>. <source xml:lang="en">Gut</source>. <year>2002</year>;<volume>51</volume>:<fpage>536</fpage>&#x02013;<lpage>539</lpage>.<pub-id pub-id-type="pmid">12235076</pub-id></mixed-citation></ref><ref id="apt15779-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="apt15779-cit-0054">
<string-name>
<surname>Stockman</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Bellamy</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Garner</surname>
<given-names>P</given-names>
</string-name>. <article-title>SARS: systematic review of treatment effects</article-title>. <source xml:lang="en">PLoS Med</source>. <year>2006</year>;<volume>3</volume>:<fpage>e343</fpage>.<pub-id pub-id-type="pmid">16968120</pub-id></mixed-citation></ref><ref id="apt15779-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="apt15779-cit-0055">
<string-name>
<surname>Arabi</surname>
<given-names>YM</given-names>
</string-name>, <string-name>
<surname>Mandourah</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Al&#x02010;Hameed</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Corticosteroid therapy for critically Ill patients with middle east respiratory syndrome</article-title>. <source xml:lang="en">Am J Respir Crit Care Med</source>. <year>2018</year>;<volume>197</volume>:<fpage>757</fpage>&#x02013;<lpage>767</lpage>.<pub-id pub-id-type="pmid">29161116</pub-id></mixed-citation></ref><ref id="apt15779-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="apt15779-cit-0056">
<string-name>
<surname>Ni</surname>
<given-names>Y&#x02010;N</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta&#x02010;analysis</article-title>. <source xml:lang="en">Crit Care</source>. <year>2019</year>;<volume>23</volume>:<fpage>99</fpage>.<pub-id pub-id-type="pmid">30917856</pub-id></mixed-citation></ref><ref id="apt15779-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="apt15779-cit-0057">
<string-name>
<surname>Lee</surname>
<given-names>DTS</given-names>
</string-name>, <string-name>
<surname>Wing</surname>
<given-names>YK</given-names>
</string-name>, <string-name>
<surname>Leung</surname>
<given-names>HCM</given-names>
</string-name>, et al. <article-title>Factors associated with psychosis among patients with severe acute respiratory syndrome: a case&#x02010;control study</article-title>. <source xml:lang="en">Clin Infect Dis</source>. <year>2004</year>;<volume>39</volume>:<fpage>1247</fpage>&#x02013;<lpage>1249</lpage>.<pub-id pub-id-type="pmid">15486852</pub-id></mixed-citation></ref><ref id="apt15779-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="apt15779-cit-0058">
<string-name>
<surname>Lee</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Allen Chan</surname>
<given-names>KC</given-names>
</string-name>, <string-name>
<surname>Hui</surname>
<given-names>DS</given-names>
</string-name>, et al. <article-title>Effects of early corticosteroid treatment on plasma SARS&#x02010;associated Coronavirus RNA concentrations in adult patients</article-title>. <source xml:lang="en">J Clin Virol</source>. <year>2004</year>;<volume>31</volume>:<fpage>304</fpage>&#x02013;<lpage>309</lpage>.<pub-id pub-id-type="pmid">15494274</pub-id></mixed-citation></ref><ref id="apt15779-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="apt15779-cit-0059">
<string-name>
<surname>Xiao</surname>
<given-names>JZ</given-names>
</string-name>, <string-name>
<surname>Ma</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Glucocorticoid&#x02010;induced diabetes in severe acute respiratory syndrome: the impact of high dosage and duration of methylprednisolone therapy</article-title>. <source xml:lang="en">Zhonghua Nei Ke Za Zhi</source>. <year>2004</year>;<volume>43</volume>:<fpage>179</fpage>&#x02013;<lpage>182</lpage>.<pub-id pub-id-type="pmid">15059370</pub-id></mixed-citation></ref><ref id="apt15779-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="apt15779-cit-0060">
<string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Relationship between glucocorticoid receptor and deficiency syndrome and the regulation of traditional Chinese medicine</article-title>. <source xml:lang="en">Zhong Xi Yi Jie He Xue Bao</source>. <year>2004</year>;<volume>2</volume>:<fpage>172</fpage>&#x02013;<lpage>174</lpage>.<pub-id pub-id-type="pmid">15339435</pub-id></mixed-citation></ref><ref id="apt15779-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="apt15779-cit-0061">
<string-name>
<surname>Tinsley</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Navabi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Williams</surname>
<given-names>ED</given-names>
</string-name>, et al. <article-title>Increased risk of influenza and influenza&#x02010;related complications among 140,480 patients with inflammatory bowel disease</article-title>. <source xml:lang="en">Inflamm Bowel Dis</source>. <year>2019</year>;<volume>25</volume>:<fpage>369</fpage>&#x02013;<lpage>376</lpage>.<pub-id pub-id-type="pmid">30020478</pub-id></mixed-citation></ref><ref id="apt15779-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="apt15779-cit-0062">
<string-name>
<surname>Long</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Martin</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Sandler</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Kappelman</surname>
<given-names>MD</given-names>
</string-name>. <article-title>Increased risk of pneumonia among patients with inflammatory bowel disease</article-title>. <source xml:lang="en">Am J Gastroenterol</source>. <year>2013</year>;<volume>108</volume>:<fpage>240</fpage>&#x02013;<lpage>248</lpage>.<pub-id pub-id-type="pmid">23295276</pub-id></mixed-citation></ref><ref id="apt15779-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="apt15779-cit-0063">
<string-name>
<surname>Orlicka</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Barnes</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Culver</surname>
<given-names>EL</given-names>
</string-name>. <article-title>Prevention of infection caused by immunosuppressive drugs in gastroenterology</article-title>. <source xml:lang="en">Ther Adv Chronic Dis</source>. <year>2013</year>;<volume>4</volume>:<fpage>167</fpage>&#x02013;<lpage>185</lpage>.<pub-id pub-id-type="pmid">23819020</pub-id></mixed-citation></ref><ref id="apt15779-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="apt15779-cit-0064">
<string-name>
<surname>Dorrington</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Selinger</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Parkes</surname>
<given-names>GC</given-names>
</string-name>, et al. <article-title>The historical role and contemporary use of corticosteroids in inflammatory bowel disease</article-title>. <source xml:lang="en">J Crohns Colitis</source>. <year>2020</year>.</mixed-citation></ref><ref id="apt15779-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="apt15779-cit-0065">
<string-name>
<surname>Sherlock</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Seow</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Steinhart</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Griffiths</surname>
<given-names>AM</given-names>
</string-name>. <article-title>Oral budesonide for induction of remission in ulcerative colitis</article-title>. <source xml:lang="en">Cochrane Database Syst Rev</source>. <year>2010</year>;<volume>10</volume>:<fpage>CD007698</fpage>.</mixed-citation></ref><ref id="apt15779-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="apt15779-cit-0066">
<string-name>
<surname>Benchimol</surname>
<given-names>EI</given-names>
</string-name>, <string-name>
<surname>Seow</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Otley</surname>
<given-names>AR</given-names>
</string-name>. <article-title>Steinhart AH. Budesonide for maintenance of remission in Crohn's disease</article-title>. <source xml:lang="en">Cochrane Database Syst Rev</source>. <year>2009</year>;<volume>1</volume>:<fpage>CD002913</fpage>.</mixed-citation></ref><ref id="apt15779-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="apt15779-cit-0067">
<string-name>
<surname>Manguso</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Bennato</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lombardi</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Efficacy and safety of oral beclomethasone dipropionate in ulcerative colitis: a systematic review and meta&#x02010;analysis</article-title>. <source xml:lang="en">PLoS ONE</source>. <year>2016</year>;<volume>11</volume>:<elocation-id>e0166455</elocation-id>.<pub-id pub-id-type="pmid">27846307</pub-id></mixed-citation></ref><ref id="apt15779-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="apt15779-cit-0068">
<string-name>
<surname>Van Assche</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Manguso</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Zibellini</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: results from a double&#x02010;blind, randomized, parallel group study</article-title>. <source xml:lang="en">Am J Gastroenterol</source>. <year>2015</year>;<volume>110</volume>:<fpage>708</fpage>&#x02013;<lpage>715</lpage>.<pub-id pub-id-type="pmid">25869389</pub-id></mixed-citation></ref><ref id="apt15779-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="apt15779-cit-0069">
<string-name>
<surname>Bonovas</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Nikolopoulos</surname>
<given-names>GK</given-names>
</string-name>, <string-name>
<surname>Lytras</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Comparative safety of systemic and low&#x02010;bioavailability steroids in inflammatory bowel disease: Systematic review and network meta&#x02010;analysis</article-title>. <source xml:lang="en">Br J Clin Pharmacol</source>. <year>2018</year>;<volume>84</volume>:<fpage>239</fpage>&#x02013;<lpage>251</lpage>.<pub-id pub-id-type="pmid">29057539</pub-id></mixed-citation></ref><ref id="apt15779-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="apt15779-cit-0070">
<string-name>
<surname>Kirchgesner</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lemaitre</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Carrat</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases</article-title>. <source xml:lang="en">Gastroenterology</source>. <year>2018</year>;<volume>155</volume>:<fpage>337</fpage>&#x02013;<lpage>46</lpage>. e10.<pub-id pub-id-type="pmid">29655835</pub-id></mixed-citation></ref><ref id="apt15779-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="apt15779-cit-0071">
<string-name>
<surname>Seksik</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Cosnes</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sokol</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine</article-title>. <source xml:lang="en">Aliment Pharmacol Ther</source>. <year>2009</year>;<volume>29</volume>:<fpage>1106</fpage>&#x02013;<lpage>1113</lpage>.<pub-id pub-id-type="pmid">19222411</pub-id></mixed-citation></ref><ref id="apt15779-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="apt15779-cit-0072">
<string-name>
<surname>Cheng</surname>
<given-names>K&#x02010;W</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>S&#x02010;C</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>W&#x02010;Y</given-names>
</string-name>, et al. <article-title>Thiopurine analogs and mycophenolic acid synergistically inhibit the papain&#x02010;like protease of Middle East respiratory syndrome coronavirus</article-title>. <source xml:lang="en">Antiviral Res</source>. <year>2015</year>;<volume>115</volume>:<fpage>9</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">25542975</pub-id></mixed-citation></ref><ref id="apt15779-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="apt15779-cit-0073">
<string-name>
<surname>Ibrahim</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ahmed</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Conway</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Carey</surname>
<given-names>JJ</given-names>
</string-name>. <article-title>Risk of infection with methotrexate therapy in inflammatory diseases: a systematic review and meta&#x02010;analysis</article-title>. <source xml:lang="en">J Clin Med</source>. <year>2019</year>;<volume>8</volume>:<fpage>15</fpage>.</mixed-citation></ref><ref id="apt15779-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="apt15779-cit-0074">
<string-name>
<surname>Conway</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Low</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Coughlan</surname>
<given-names>RJ</given-names>
</string-name>, et al. <article-title>Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta&#x02010;analysis of randomised controlled trials</article-title>. <source xml:lang="en">BMJ</source>. <year>2015</year>;<volume>350</volume>:<fpage>h1269</fpage>.<pub-id pub-id-type="pmid">25770113</pub-id></mixed-citation></ref><ref id="apt15779-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="apt15779-cit-0075">
<string-name>
<surname>Lichtenstein</surname>
<given-names>GR</given-names>
</string-name>, <string-name>
<surname>Feagan</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>
<given-names>RD</given-names>
</string-name>, et al. <article-title>Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow&#x02010;up in the TREAT registry</article-title>. <source xml:lang="en">Am J Gastroenterol</source>. <year>2012</year>;<volume>107</volume>:<fpage>1409</fpage>&#x02013;<lpage>1422</lpage>.<pub-id pub-id-type="pmid">22890223</pub-id></mixed-citation></ref><ref id="apt15779-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="apt15779-cit-0076">
<string-name>
<surname>Shah</surname>
<given-names>ED</given-names>
</string-name>, <string-name>
<surname>Farida</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Siegel</surname>
<given-names>CA</given-names>
</string-name>, et al. <article-title>Risk for overall infection with anti&#x02010;TNF and anti&#x02010;integrin agents used in IBD: a systematic review and meta&#x02010;analysis</article-title>. <source xml:lang="en">Inflamm Bowel Dis</source>. <year>2017</year>;<volume>23</volume>:<fpage>570</fpage>&#x02013;<lpage>577</lpage>.<pub-id pub-id-type="pmid">28230558</pub-id></mixed-citation></ref><ref id="apt15779-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="apt15779-cit-0077">
<string-name>
<surname>Singh</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Facciorusso</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Dulai</surname>
<given-names>PS</given-names>
</string-name>, et al. <article-title>Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta&#x02010;analysis</article-title>. <source xml:lang="en">Clin Gastroenterol Hepatol</source>. <year>2020</year>;<volume>18</volume>:<fpage>69</fpage>&#x02013;<lpage>81</lpage>. e3<pub-id pub-id-type="pmid">30876964</pub-id></mixed-citation></ref><ref id="apt15779-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="apt15779-cit-0078">
<string-name>
<surname>Lv</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yi</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Anti&#x02010;TNF&#x02010;alpha therapy for patients with sepsis: a systematic meta&#x02010;analysis</article-title>. <source xml:lang="en">Int J Clin Pract</source>. <year>2014</year>;<volume>68</volume>:<fpage>520</fpage>&#x02013;<lpage>528</lpage>.<pub-id pub-id-type="pmid">24548627</pub-id></mixed-citation></ref><ref id="apt15779-bib-0079"><label>79</label><mixed-citation publication-type="journal" id="apt15779-cit-0079">
<string-name>
<surname>Cheng</surname>
<given-names>VC</given-names>
</string-name>, <string-name>
<surname>Lau</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Woo</surname>
<given-names>PC</given-names>
</string-name>, <string-name>
<surname>Yuen</surname>
<given-names>KY</given-names>
</string-name>. <article-title>Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection</article-title>. <source xml:lang="en">Clin Microbiol Rev</source>. <year>2007</year>;<volume>20</volume>:<fpage>660</fpage>&#x02013;<lpage>694</lpage>.<pub-id pub-id-type="pmid">17934078</pub-id></mixed-citation></ref><ref id="apt15779-bib-0080"><label>80</label><mixed-citation publication-type="journal" id="apt15779-cit-0080">
<string-name>
<surname>Feagan</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Sandborn</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Gasink</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Ustekinumab as induction and maintenance therapy for Crohn's disease</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2016</year>;<volume>375</volume>:<fpage>1946</fpage>&#x02013;<lpage>1960</lpage>.<pub-id pub-id-type="pmid">27959607</pub-id></mixed-citation></ref><ref id="apt15779-bib-0081"><label>81</label><mixed-citation publication-type="journal" id="apt15779-cit-0081">
<string-name>
<surname>Kalb</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Fiorentino</surname>
<given-names>DF</given-names>
</string-name>, <string-name>
<surname>Lebwohl</surname>
<given-names>MG</given-names>
</string-name>, et al. <article-title>Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR)</article-title>. <source xml:lang="en">JAMA Dermatol</source>. <year>2015</year>;<volume>151</volume>:<fpage>961</fpage>&#x02013;<lpage>969</lpage>.<pub-id pub-id-type="pmid">25970800</pub-id></mixed-citation></ref><ref id="apt15779-bib-0082"><label>82</label><mixed-citation publication-type="journal" id="apt15779-cit-0082">
<string-name>
<surname>Hanauer</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Sandborn</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Feagan</surname>
<given-names>BG</given-names>
</string-name>, et al. <article-title>IM&#x02010;UNITI: three&#x02010;year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn's disease</article-title>. <source xml:lang="en">J Crohns Colitis</source>. <year>2020</year>;<volume>14</volume>:<fpage>23</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">31158271</pub-id></mixed-citation></ref><ref id="apt15779-bib-0083"><label>83</label><mixed-citation publication-type="journal" id="apt15779-cit-0083">
<string-name>
<surname>Bye</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Jairath</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Travis</surname>
<given-names>SPL</given-names>
</string-name>. <article-title>Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease</article-title>. <source xml:lang="en">Aliment Pharmacol Ther</source>. <year>2017</year>;<volume>46</volume>:<fpage>3</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">28449273</pub-id></mixed-citation></ref><ref id="apt15779-bib-0084"><label>84</label><mixed-citation publication-type="journal" id="apt15779-cit-0084">
<string-name>
<surname>Mocko</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kawalec</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Pilc</surname>
<given-names>A</given-names>
</string-name>. <article-title>Safety profile of biologic drugs in the therapy of Crohn disease: a systematic review and network meta&#x02010;analysis</article-title>. <source xml:lang="en">Pharmacol Rep</source>. <year>2016</year>;<volume>68</volume>:<fpage>1237</fpage>&#x02013;<lpage>1243</lpage>.<pub-id pub-id-type="pmid">27686963</pub-id></mixed-citation></ref><ref id="apt15779-bib-0085"><label>85</label><mixed-citation publication-type="journal" id="apt15779-cit-0085">
<string-name>
<surname>Mocko</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kawalec</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Pilc</surname>
<given-names>A</given-names>
</string-name>. <article-title>Safety profile of biologic drugs in the therapy of ulcerative colitis: a systematic review and network meta&#x02010;analysis</article-title>. <source xml:lang="en">Pharmacotherapy</source>. <year>2016</year>;<volume>36</volume>:<fpage>870</fpage>&#x02013;<lpage>879</lpage>.<pub-id pub-id-type="pmid">27312826</pub-id></mixed-citation></ref><ref id="apt15779-bib-0086"><label>86</label><mixed-citation publication-type="journal" id="apt15779-cit-0086">
<string-name>
<surname>Colombel</surname>
<given-names>J&#x02010;F</given-names>
</string-name>, <string-name>
<surname>Sands</surname>
<given-names>BE</given-names>
</string-name>, <string-name>
<surname>Rutgeerts</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>The safety of vedolizumab for ulcerative colitis and Crohn's disease</article-title>. <source xml:lang="en">Gut</source>. <year>2017</year>;<volume>66</volume>:<fpage>839</fpage>&#x02013;<lpage>851</lpage>.<pub-id pub-id-type="pmid">26893500</pub-id></mixed-citation></ref><ref id="apt15779-bib-0087"><label>87</label><mixed-citation publication-type="journal" id="apt15779-cit-0087">
<string-name>
<surname>Bourges</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Chevaleyre</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Differential expression of adhesion molecules and chemokines between nasal and small intestinal mucosae: implications for T&#x02010; and sIgA+ B&#x02010;lymphocyte recruitment</article-title>. <source xml:lang="en">Immunology</source>. <year>2007</year>;<volume>122</volume>:<fpage>551</fpage>&#x02013;<lpage>561</lpage>.<pub-id pub-id-type="pmid">17635614</pub-id></mixed-citation></ref><ref id="apt15779-bib-0088"><label>88</label><mixed-citation publication-type="journal" id="apt15779-cit-0088">
<string-name>
<surname>Van Assche</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Vermeire</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ballet</surname>
<given-names>V</given-names>
</string-name>, et al. <article-title>Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial</article-title>. <source xml:lang="en">Gut</source>. <year>2012</year>;<volume>61</volume>:<fpage>229</fpage>&#x02013;<lpage>234</lpage>.<pub-id pub-id-type="pmid">21948942</pub-id></mixed-citation></ref><ref id="apt15779-bib-0089"><label>89</label><mixed-citation publication-type="journal" id="apt15779-cit-0089">
<string-name>
<surname>Winthrop</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Melmed</surname>
<given-names>GY</given-names>
</string-name>, <string-name>
<surname>Vermeire</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib</article-title>. <source xml:lang="en">Inflamm Bowel Dis</source>. <year>2018</year>;<volume>24</volume>:<fpage>2258</fpage>&#x02013;<lpage>2265</lpage>.<pub-id pub-id-type="pmid">29850873</pub-id></mixed-citation></ref><ref id="apt15779-bib-0090"><label>90</label><mixed-citation publication-type="journal" id="apt15779-cit-0090">
<string-name>
<surname>Wollenhaupt</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>EB</given-names>
</string-name>, <string-name>
<surname>Curtis</surname>
<given-names>JR</given-names>
</string-name>, et al. <article-title>Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open&#x02010;label, long&#x02010;term extension study</article-title>. <source xml:lang="en">Arthritis Res Ther</source>. <year>2019</year>;<volume>21</volume>:<fpage>89</fpage>.<pub-id pub-id-type="pmid">30953540</pub-id></mixed-citation></ref><ref id="apt15779-bib-0091"><label>91</label><mixed-citation publication-type="journal" id="apt15779-cit-0091">
<string-name>
<surname>Sandborn</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Su</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Sands</surname>
<given-names>BE</given-names>
</string-name>, et al. <article-title>Tofacitinib as induction and maintenance therapy for ulcerative colitis</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2017</year>;<volume>376</volume>:<fpage>1723</fpage>&#x02013;<lpage>1736</lpage>.<pub-id pub-id-type="pmid">28467869</pub-id></mixed-citation></ref><ref id="apt15779-bib-0092"><label>92</label><mixed-citation publication-type="journal" id="apt15779-cit-0092">
<string-name>
<surname>Harigai</surname>
<given-names>M</given-names>
</string-name>. <article-title>Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis</article-title>. <source xml:lang="en">Rheumatology (Oxford)</source>. <year>2019</year>;<volume>58</volume>(<issue>Suppl 1</issue>):<fpage>i34</fpage>&#x02013;<lpage>i42</lpage>.<pub-id pub-id-type="pmid">30806708</pub-id></mixed-citation></ref><ref id="apt15779-bib-0093"><label>93</label><mixed-citation publication-type="journal" id="apt15779-cit-0093">
<string-name>
<surname>Weisshof</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Aharoni Golan</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sossenheimer</surname>
<given-names>PH</given-names>
</string-name>, et al. <article-title>Real&#x02010;world experience with tofacitinib in IBD at a Tertiary Center</article-title>. <source xml:lang="en">Dig Dis Sci</source>. <year>2019</year>;<volume>64</volume>:<fpage>1945</fpage>&#x02013;<lpage>1951</lpage>.<pub-id pub-id-type="pmid">30734234</pub-id></mixed-citation></ref><ref id="apt15779-bib-0094"><label>94</label><mixed-citation publication-type="journal" id="apt15779-cit-0094">
<string-name>
<surname>Stebbing</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Phelan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Griffin</surname>
<given-names>I</given-names>
</string-name>, et al. <article-title>COVID&#x02010;19: combining antiviral and anti&#x02010;inflammatory treatments</article-title>. <source xml:lang="en">Lancet Infect Dis</source>. <year>2020</year>;<volume>20</volume>:<fpage>400</fpage>&#x02013;<lpage>402</lpage>.<pub-id pub-id-type="pmid">32113509</pub-id></mixed-citation></ref><ref id="apt15779-bib-0095"><label>95</label><mixed-citation publication-type="miscellaneous" id="apt15779-cit-0095">
<collab collab-type="authors">European Centre for Disease Prevention and Control</collab>
. <article-title>Technical Report: Guidance for discharge and ending isolation in the context of widespread community transmission of COVID&#x02010;19 &#x02013; first update</article-title>. <ext-link ext-link-type="uri" xlink:href="https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-guidance-discharge-and-ending-isolation-first%2520update.pdf">https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-guidance-discharge-and-ending-isolation-first%2520update.pdf</ext-link>. Accessed April 11, 2020.</mixed-citation></ref><ref id="apt15779-bib-0096"><label>96</label><mixed-citation publication-type="journal" id="apt15779-cit-0096">
<string-name>
<surname>Ananthakrishnan</surname>
<given-names>AN</given-names>
</string-name>, <string-name>
<surname>McGinley</surname>
<given-names>EL</given-names>
</string-name>. <article-title>Infection&#x02010;related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases</article-title>. <source xml:lang="en">J Crohns Colitis</source>. <year>2013</year>;<volume>7</volume>:<fpage>107</fpage>&#x02013;<lpage>112</lpage>.<pub-id pub-id-type="pmid">22440891</pub-id></mixed-citation></ref><ref id="apt15779-bib-0097"><label>97</label><mixed-citation publication-type="journal" id="apt15779-cit-0097">
<string-name>
<surname>Fong</surname>
<given-names>MW</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>JY</given-names>
</string-name>, et al. <article-title>Nonpharmaceutical measures for pandemic influenza in nonhealthcare settings&#x02010;social distancing measures</article-title>. <source xml:lang="en">Emerg Infect Dis</source>. <year>2020</year>;<volume>26</volume>:<fpage>976</fpage>&#x02013;<lpage>984</lpage>.<pub-id pub-id-type="pmid">32027585</pub-id></mixed-citation></ref><ref id="apt15779-bib-0098"><label>98</label><mixed-citation publication-type="journal" id="apt15779-cit-0098">
<string-name>
<surname>Ahmed</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Zviedrite</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Uzicanin</surname>
<given-names>A</given-names>
</string-name>. <article-title>Effectiveness of workplace social distancing measures in reducing influenza transmission: a systematic review</article-title>. <source xml:lang="en">BMC Public Health</source>. <year>2018</year>;<volume>18</volume>:<fpage>518</fpage>.<pub-id pub-id-type="pmid">29669545</pub-id></mixed-citation></ref><ref id="apt15779-bib-0099"><label>99</label><mixed-citation publication-type="journal" id="apt15779-cit-0099">
<string-name>
<surname>Hollander</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Carr</surname>
<given-names>BG</given-names>
</string-name>. <article-title>Virtually perfect? Telemedicine for Covid&#x02010;19</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2020</year>;<volume>382</volume>:<fpage>1679</fpage>&#x02013;<lpage>1681</lpage>
<pub-id pub-id-type="pmid">32160451</pub-id></mixed-citation></ref><ref id="apt15779-bib-0100"><label>100</label><mixed-citation publication-type="journal" id="apt15779-cit-0100">
<string-name>
<surname>Clare</surname>
<given-names>DF</given-names>
</string-name>, <string-name>
<surname>Alexander</surname>
<given-names>FC</given-names>
</string-name>, <string-name>
<surname>Mike</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease</article-title>. <source xml:lang="en">Eur J Gastroenterol Hepatol</source>. <year>2009</year>;<volume>21</volume>:<fpage>71</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">19060632</pub-id></mixed-citation></ref><ref id="apt15779-bib-0101"><label>101</label><mixed-citation publication-type="miscellaneous" id="apt15779-cit-0101">
<collab collab-type="authors">World Health Organisation</collab>
.<article-title>A multi&#x02010;centre, adaptive, randomized, double&#x02010;blind, placebocontrolled clinical trial of the safety and efficacy of investigational therapeutics for the treatment of COVID&#x02010;19 in hospitalized patients</article-title>.<year>2020</year>.</mixed-citation></ref><ref id="apt15779-bib-0102"><label>102</label><mixed-citation publication-type="journal" id="apt15779-cit-0102">
<string-name>
<surname>Agostini</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Andres</surname>
<given-names>EL</given-names>
</string-name>, <string-name>
<surname>Sims</surname>
<given-names>AC</given-names>
</string-name>, et al. <article-title>Coronavirus susceptibility to the antiviral remdesivir (GS&#x02010;5734) is mediated by the viral polymerase and the proofreading exoribonuclease</article-title>. <source xml:lang="en">mBio</source>. <year>2018</year>;<volume>9</volume>.</mixed-citation></ref><ref id="apt15779-bib-0103"><label>103</label><mixed-citation publication-type="journal" id="apt15779-cit-0103">
<string-name>
<surname>Wang</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Cao</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019&#x02010;nCoV) in vitro</article-title>. <source xml:lang="en">Cell Res</source>. <year>2020</year>;<volume>30</volume>:<fpage>269</fpage>&#x02013;<lpage>271</lpage>.<pub-id pub-id-type="pmid">32020029</pub-id></mixed-citation></ref><ref id="apt15779-bib-0104"><label>104</label><mixed-citation publication-type="journal" id="apt15779-cit-0104">
<string-name>
<surname>Lu</surname>
<given-names>H</given-names>
</string-name>. <article-title>Drug treatment options for the 2019&#x02010;new coronavirus (2019&#x02010;nCoV)</article-title>. <source xml:lang="en">BioSci Trends</source>. <year>2020</year>.</mixed-citation></ref><ref id="apt15779-bib-0105"><label>105</label><mixed-citation publication-type="journal" id="apt15779-cit-0105">
<string-name>
<surname>Chu</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>VC</given-names>
</string-name>, <string-name>
<surname>Hung</surname>
<given-names>IF</given-names>
</string-name>, et al. <article-title>Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings</article-title>. <source xml:lang="en">Thorax</source>. <year>2004</year>;<volume>59</volume>:<fpage>252</fpage>&#x02013;<lpage>256</lpage>.<pub-id pub-id-type="pmid">14985565</pub-id></mixed-citation></ref><ref id="apt15779-bib-0106"><label>106</label><mixed-citation publication-type="journal" id="apt15779-cit-0106">
<string-name>
<surname>Chan</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Yao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yeung</surname>
<given-names>ML</given-names>
</string-name>, et al. <article-title>Treatment with lopinavir/ritonavir or interferon&#x02010;beta1b improves outcome of MERS&#x02010;CoV infection in a nonhuman primate model of common marmoset</article-title>. <source xml:lang="en">J Infect Dis</source>. <year>2015</year>;<volume>212</volume>:<fpage>1904</fpage>&#x02013;<lpage>1913</lpage>.<pub-id pub-id-type="pmid">26198719</pub-id></mixed-citation></ref><ref id="apt15779-bib-0107"><label>107</label><mixed-citation publication-type="journal" id="apt15779-cit-0107">
<string-name>
<surname>Cao</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wen</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>A trial of lopinavir&#x02010;ritonavir in adults hospitalized with severe Covid&#x02010;19</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2020</year>.</mixed-citation></ref><ref id="apt15779-bib-0108"><label>108</label><mixed-citation publication-type="journal" id="apt15779-cit-0108">
<string-name>
<surname>Devaux</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Rolain</surname>
<given-names>J&#x02010;M</given-names>
</string-name>, <string-name>
<surname>Colson</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Raoult</surname>
<given-names>D</given-names>
</string-name>. <article-title>New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID&#x02010;19?</article-title>
<source xml:lang="en">Int J Antimicrob Agents</source>. <year>2020</year>.</mixed-citation></ref><ref id="apt15779-bib-0109"><label>109</label><mixed-citation publication-type="journal" id="apt15779-cit-0109">
<string-name>
<surname>Colson</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Rolain</surname>
<given-names>J&#x02010;M</given-names>
</string-name>, <string-name>
<surname>Lagier</surname>
<given-names>J&#x02010;C</given-names>
</string-name>, et al. <article-title>Chloroquine and hydroxychloroquine as available weapons to fight COVID&#x02010;19</article-title>. <source xml:lang="en">Int J Antimicrob Agents</source>. <year>2020</year>;105932.</mixed-citation></ref><ref id="apt15779-bib-0110"><label>110</label><mixed-citation publication-type="journal" id="apt15779-cit-0110">
<string-name>
<surname>Colson</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Rolain</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Raoult</surname>
<given-names>D</given-names>
</string-name>. <article-title>Chloroquine for the 2019 novel coronavirus SARS&#x02010;CoV&#x02010;2</article-title>. <source xml:lang="en">Int J Antimicrob Agents</source>. <year>2020</year>;<volume>55</volume>:<fpage>105923</fpage>.<pub-id pub-id-type="pmid">32070753</pub-id></mixed-citation></ref><ref id="apt15779-bib-0111"><label>111</label><mixed-citation publication-type="journal" id="apt15779-cit-0111">
<string-name>
<surname>Gautret</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lagier</surname>
<given-names>J&#x02010;C</given-names>
</string-name>, <string-name>
<surname>Parola</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Hydroxychloroquine and azithromycin as a treatment of COVID&#x02010;19: results of an open&#x02010;label non&#x02010;randomized clinical trial</article-title>. <source xml:lang="en">Int J Antimicrob Agents</source>. <year>2020</year>;105949.</mixed-citation></ref><ref id="apt15779-bib-0112"><label>112</label><mixed-citation publication-type="journal" id="apt15779-cit-0112">
<string-name>
<surname>Li</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>De Clercq</surname>
<given-names>E</given-names>
</string-name>. <article-title>Therapeutic options for the 2019 novel coronavirus (2019&#x02010;nCoV)</article-title>. <source xml:lang="en">Nat Rev Drug Discov</source>. <year>2020</year>;<volume>19</volume>:<fpage>149</fpage>&#x02013;<lpage>150</lpage>.<pub-id pub-id-type="pmid">32127666</pub-id></mixed-citation></ref><ref id="apt15779-bib-0113"><label>113</label><mixed-citation publication-type="journal" id="apt15779-cit-0113">
<string-name>
<surname>Chang</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>Z</given-names>
</string-name>, et al. <article-title>Faviiravir versus arbidol for COVID&#x02010; 19: a randomized clinical trial</article-title>. [In press]. <source xml:lang="en">medRxiv</source>. <year>2020</year>.</mixed-citation></ref><ref id="apt15779-bib-0114"><label>114</label><mixed-citation publication-type="miscellaneous" id="apt15779-cit-0114">
<article-title>Chinese Clinical Trials Registry 2020</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/searchprojen.aspx?title=COVID-19%26officialname=%26subjectid=%26secondaryid=%26applier=%26studyleader=%26ethicalcommitteesanction=%26sponsor=%26studyailment=%26studyailmentcode=%26studytype=0%26studystage=0%26studydesign=0%26minstudyexecutetime=%26maxstudyexecutetime=%26recruitmentstatus=0%26gender=0%26agreetosign=%26secsponsor=%26regno=%26regstatus=0%26country=%26province=%26city=%26institution=%26institutionlevel=%26measure=%26intercode=%26sourceofspends=%26createyear=0%26isuploadrf=%26whetherpublic=%26btngo=btn%26verifycode=%26page=1">http://www.chictr.org.cn/searchprojen.aspx?title=COVID-19%26officialname=%26subjectid=%26secondaryid=%26applier=%26studyleader=%26ethicalcommitteesanction=%26sponsor=%26studyailment=%26studyailmentcode=%26studytype=0%26studystage=0%26studydesign=0%26minstudyexecutetime=%26maxstudyexecutetime=%26recruitmentstatus=0%26gender=0%26agreetosign=%26secsponsor=%26regno=%26regstatus=0%26country=%26province=%26city=%26institution=%26institutionlevel=%26measure=%26intercode=%26sourceofspends=%26createyear=0%26isuploadrf=%26whetherpublic=%26btngo=btn%26verifycode=%26page=1</ext-link>
</mixed-citation></ref><ref id="apt15779-bib-0115"><label>115</label><mixed-citation publication-type="miscellaneous" id="apt15779-cit-0115">
<string-name>
<surname>Schwartz</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>King</surname>
<given-names>C&#x02010;C</given-names>
</string-name>, <string-name>
<surname>Yen</surname>
<given-names>M&#x02010;Y</given-names>
</string-name>.Protecting healthcare workers during the coronavirus disease 2019 (COVID&#x02010;19) outbreak: lessons from Taiwan&#x02019;s severe acute respiratory syndrome response.<article-title>Clin Infect Dis</article-title>. <year>2020</year>.</mixed-citation></ref><ref id="apt15779-bib-0116"><label>116</label><mixed-citation publication-type="journal" id="apt15779-cit-0116">
<string-name>
<surname>Zhou</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Du</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Clinical course and risk factors for mortality of adult inpatients with COVID&#x02010;19 in Wuhan, China: a retrospective cohort study</article-title>. <source xml:lang="en">Lancet</source>. <year>2020</year>;<volume>395</volume>:<fpage>1054</fpage>&#x02013;<lpage>1062</lpage>.<pub-id pub-id-type="pmid">32171076</pub-id></mixed-citation></ref><ref id="apt15779-bib-0117"><label>117</label><mixed-citation publication-type="journal" id="apt15779-cit-0117">
<string-name>
<surname>Phan</surname>
<given-names>LT</given-names>
</string-name>, <string-name>
<surname>Maita</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Mortiz</surname>
<given-names>DC</given-names>
</string-name>, et al. <article-title>Contact and self&#x02010;contact patterns of healthcare workers: implications for infection prevention and control</article-title>. <source xml:lang="en">Clin Infect Dis</source>. <year>2019</year>;<volume>69</volume>(<issue>Supplement_3</issue>):<fpage>S178</fpage>&#x02013;<lpage>S184</lpage>.<pub-id pub-id-type="pmid">31517975</pub-id></mixed-citation></ref><ref id="apt15779-bib-0118"><label>118</label><mixed-citation publication-type="journal" id="apt15779-cit-0118">
<string-name>
<surname>Kuenzig</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Rezaie</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kaplan</surname>
<given-names>GG</given-names>
</string-name>, et al. <article-title>Budesonide for the induction and maintenance of remission in Crohn's disease: systematic review and meta&#x02010;analysis for the Cochrane collaboration</article-title>. <source xml:lang="en">J Can Assoc Gastroenterol</source>. <year>2018</year>;<volume>1</volume>:<fpage>159</fpage>&#x02013;<lpage>173</lpage>.<pub-id pub-id-type="pmid">30656288</pub-id></mixed-citation></ref><ref id="apt15779-bib-0119"><label>119</label><mixed-citation publication-type="journal" id="apt15779-cit-0119">
<string-name>
<surname>Rizzello</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Gionchetti</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>D'Arienzo</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double&#x02010;blind placebo&#x02010;controlled study</article-title>. <source xml:lang="en">Aliment Pharmacol Ther</source>. <year>2002</year>;<volume>16</volume>(<issue>6</issue>):<fpage>1109</fpage>&#x02013;<lpage>1116</lpage>.<pub-id pub-id-type="pmid">12030952</pub-id></mixed-citation></ref><ref id="apt15779-bib-0120"><label>120</label><mixed-citation publication-type="journal" id="apt15779-cit-0120">
<string-name>
<surname>Feagan</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Bhayat</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Khalid</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Respiratory tract infections in patients with inflammatory bowel disease: safety analyses from vedolizumab clinical trials</article-title>. <source xml:lang="en">J Crohns Colitis</source>. <year>2018</year>;<volume>12</volume>:<fpage>905</fpage>&#x02013;<lpage>919</lpage>.<pub-id pub-id-type="pmid">29788248</pub-id></mixed-citation></ref><ref id="apt15779-bib-0121"><label>121</label><mixed-citation publication-type="miscellaneous" id="apt15779-cit-0121">
<article-title>Tofacitinib [Internet].Truven Health Analytics</article-title>. <year>2020</year> [cited 14 March 2020]. <ext-link ext-link-type="uri" xlink:href="http://www.micromedexsolutions.com">http://www.micromedexsolutions.com</ext-link>. Subscription required to view.</mixed-citation></ref><ref id="apt15779-bib-0122"><label>122</label><mixed-citation publication-type="miscellaneous" id="apt15779-cit-0122">
<article-title>Tofacitinib [Internet].Truven Health Analytics</article-title>. <year>2020</year> [cited 14 March 2020]. <ext-link ext-link-type="uri" xlink:href="http://www.micromedexsolutions.com">http://www.micromedexsolutions.com</ext-link>. Subscription required to view.</mixed-citation></ref><ref id="apt15779-bib-0123"><label>123</label><mixed-citation publication-type="journal" id="apt15779-cit-0123">
<string-name>
<surname>Cohen</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Mariette</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>Long&#x02010;term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials</article-title>. <source xml:lang="en">Ann Rheum Dis</source>. <year>2017</year>;<volume>76</volume>:<fpage>1253</fpage>&#x02013;<lpage>1262</lpage>.<pub-id pub-id-type="pmid">28143815</pub-id></mixed-citation></ref><ref id="apt15779-bib-0124"><label>124</label><mixed-citation publication-type="journal" id="apt15779-cit-0124">
<string-name>
<surname>Derijks</surname>
<given-names>LJJ</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Hommes</surname>
<given-names>DW</given-names>
</string-name>, <string-name>
<surname>van Bodegraven</surname>
<given-names>AA</given-names>
</string-name>. <article-title>Clinical pharmacokinetic and pharmacodynamic considerations in the treatment of inflammatory bowel disease</article-title>. <source xml:lang="en">Clin Pharmacokinet</source>. <year>2018</year>;<volume>57</volume>:<fpage>1075</fpage>&#x02013;<lpage>1106</lpage>.<pub-id pub-id-type="pmid">29512050</pub-id></mixed-citation></ref><ref id="apt15779-bib-0125"><label>125</label><mixed-citation publication-type="journal" id="apt15779-cit-0125">
<string-name>
<surname>Gisbert</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Nino</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Cara</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Rodrigo</surname>
<given-names>L</given-names>
</string-name>. <article-title>Comparative effectiveness of azathioprine in Crohn's disease and ulcerative colitis: prospective, long&#x02010;term, follow&#x02010;up study of 394 patients</article-title>. <source xml:lang="en">Aliment Pharmacol Ther</source>. <year>2008</year>;<volume>28</volume>:<fpage>228</fpage>&#x02013;<lpage>238</lpage>.<pub-id pub-id-type="pmid">18485129</pub-id></mixed-citation></ref><ref id="apt15779-bib-0126"><label>126</label><mixed-citation publication-type="journal" id="apt15779-cit-0126">
<string-name>
<surname>Ben&#x02010;Horin</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Van Assche</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Chowers</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Pharmacokinetics and immune reconstitution following discontinuation of thiopurine analogues: implications for drug withdrawal strategies</article-title>. <source xml:lang="en">J Crohns Colitis</source>. <year>2018</year>;<volume>12</volume>:<fpage>1410</fpage>&#x02013;<lpage>1417</lpage>.<pub-id pub-id-type="pmid">30169593</pub-id></mixed-citation></ref><ref id="apt15779-bib-0127"><label>127</label><mixed-citation publication-type="journal" id="apt15779-cit-0127">
<string-name>
<surname>Vande Casteele</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Baert</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Bian</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>subcutaneous absorption contributes to observed interindividual variability in adalimumab serum concentrations in Crohn's disease: a prospective multicentre study</article-title>. <source xml:lang="en">J Crohns Colitis</source>. <year>2019</year>;<volume>13</volume>:<fpage>1248</fpage>&#x02013;<lpage>1256</lpage>.<pub-id pub-id-type="pmid">30820530</pub-id></mixed-citation></ref><ref id="apt15779-bib-0128"><label>128</label><mixed-citation publication-type="journal" id="apt15779-cit-0128">
<string-name>
<surname>Ternant</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Bejan&#x02010;Angoulvant</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Passot</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Clinical pharmacokinetics and pharmacodynamics of monoclonal antibodies approved to treat rheumatoid arthritis</article-title>. <source xml:lang="en">Clin Pharmacokinet</source>. <year>2015</year>;<volume>54</volume>:<fpage>1107</fpage>&#x02013;<lpage>1123</lpage>.<pub-id pub-id-type="pmid">26123705</pub-id></mixed-citation></ref><ref id="apt15779-bib-0129"><label>129</label><mixed-citation publication-type="journal" id="apt15779-cit-0129">
<string-name>
<surname>Klotz</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Teml</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Schwab</surname>
<given-names>M</given-names>
</string-name>. <article-title>Clinical pharmacokinetics and use of infliximab</article-title>. <source xml:lang="en">Clin Pharmacokinet</source>. <year>2007</year>;<volume>48</volume>:<fpage>645</fpage>&#x02013;<lpage>660</lpage>.</mixed-citation></ref><ref id="apt15779-bib-0130"><label>130</label><mixed-citation publication-type="journal" id="apt15779-cit-0130">
<string-name>
<surname>Ternant</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Aubourg</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Magdelaine&#x02010;Beuzelin</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Infliximab pharmacokinetics in inflammatory bowel disease patients</article-title>. <source xml:lang="en">Ther Drug Monit</source>. <year>2008</year>;<volume>30</volume>:<fpage>523</fpage>&#x02013;<lpage>529</lpage>.<pub-id pub-id-type="pmid">18641542</pub-id></mixed-citation></ref><ref id="apt15779-bib-0131"><label>131</label><mixed-citation publication-type="journal" id="apt15779-cit-0131">
<string-name>
<surname>Hemperly</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Vande</surname>
<given-names>CN</given-names>
</string-name>. <article-title>Clinical pharmacokinetics and pharmacodynamics of infliximab in the treatment of inflammatory bowel disease</article-title>. <source xml:lang="en">Clin Pharmacokinet</source>. <year>2018</year>;<volume>57</volume>:<fpage>929</fpage>&#x02013;<lpage>942</lpage>.<pub-id pub-id-type="pmid">29330783</pub-id></mixed-citation></ref><ref id="apt15779-bib-0132"><label>132</label><mixed-citation publication-type="journal" id="apt15779-cit-0132">
<string-name>
<surname>Tian</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Cronstein</surname>
<given-names>BN</given-names>
</string-name>. <article-title>Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis</article-title>. <source xml:lang="en">Bull NYU Hosp Jt Dis</source>. <year>2007</year>;<volume>65</volume>:<fpage>168</fpage>&#x02013;<lpage>173</lpage>.<pub-id pub-id-type="pmid">17922664</pub-id></mixed-citation></ref><ref id="apt15779-bib-0133"><label>133</label><mixed-citation publication-type="journal" id="apt15779-cit-0133">
<string-name>
<surname>Best</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Capparelli</surname>
<given-names>EV</given-names>
</string-name>, <string-name>
<surname>Diep</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children</article-title>. <source xml:lang="en">J Acquir Immune Defic Syndr</source>. <year>2011</year>;<volume>58</volume>:<fpage>385</fpage>&#x02013;<lpage>391</lpage>.<pub-id pub-id-type="pmid">21876444</pub-id></mixed-citation></ref><ref id="apt15779-bib-0134"><label>134</label><mixed-citation publication-type="journal" id="apt15779-cit-0134">
<string-name>
<surname>Quetglas</surname>
<given-names>EG</given-names>
</string-name>, <string-name>
<surname>Armuzzi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Wigge</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Review article: the pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment</article-title>. <source xml:lang="en">Eur J Clin Pharmacol</source>. <year>2015</year>;<volume>71</volume>:<fpage>773</fpage>&#x02013;<lpage>799</lpage>.<pub-id pub-id-type="pmid">26008212</pub-id></mixed-citation></ref></ref-list></back></article>